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Abstract
The majority of the reported genetic disorders in the UAE population are of
the autosomal recessive type, which is mainly due to high rates of consanguinity
within the UAE national population, and within a significant proportion of other
UAE expatriate communities; such as Arabs and Pakistanis. It is estimated that more
than 50% of all marriages among Emiratis occur between biologically related
couples, with first cousin marriages being the highest. That could be attributed to
sociocultural values in the region. Successful management of genetic diseases can be
achieved by the implementation of effective preventative programs that could help
reduce the number of new cases, and provide early diagnosis to potentially improve
disease management. For these desired outcomes to be achieved, it is imperative to
identify the molecular causes (i.e. disease-causing genes and mutations) of such
disorders. Therefore, the aim of this study is to elucidate the molecular pathology and
cellular mechanisms of a group of recessive disorders affecting Emirati and
expatriate families in the UAE. Whole exome sequencing, together with
homozygosity mapping and segregation analyses, were performed on the recruited
families to elucidate the causative genes and mutations. Where necessary,
bioinformatics in silico analyses coupled with cellular and other functional studies
were performed to confirm pathogenicity and uncover the cellular mechanisms of the
studied disease phenotypes. In this dissertation, I report the identification of two
novel compound heterozygous mutations in Multiple PDZ domain (MPDZ) gene
causing congenital hydrocephalus, and provide experimental evidence on their
pathogenesis and mechanisms of action. In addition, I report the identification of a
novel mutation in Xylosyltransferase I (XYLT1) gene responsible for Desbuquois

viii
dysplasia II (DBQDII), and provide evidence on the involvement of the endoplasmic
reticulum (ER) quality control in the cellular mechanism of several DBQDII-causing
mutations, including, the newly identified one. Furthermore, I provide preliminary
data on candidate genes in two families affected by suspected monogenic intellectual
disability syndromes. Overall, this dissertation provides evidence on the
pathogenicity of several mutations and associated cellular mechanisms. The
outcomes of this project will likely be valuable for implementing effective preventive
strategies at least for the extended family members of the affected individuals.

Keywords: Autosomal recessive disorders, Desbuquois dysplasia II (DBQDII),
congenital hydrocephalus, XYLT1, MPDZ, whole exome sequencing.
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)Title and Abstract (in Arabic

دراسات جينية وخلوية ترسخ ميكانيكية وطريقة تطور المرض الناتج عن الطفرات
الجينية في بعض األمراض الوراثية المتنحية
الملخص

أغلبية األمراض الوراثية بين سكان ومواطني دولة اإلمارات العربية المتحدة هي من
األمراض الوراثية المتنحية ،ومن أهم أسباب ذلك ارتفاع معدل زواج األقارب بين مواطني
الدولة وبين بعض السكان القاطنين مثل العرب والباكستانيين .نسبة الزواج من األقارب عند
مواطني الدولة تفوق ال  ،%05حيث أن معظمها من زواج أبناء العم من الدرجة األولى .يعود
ذلك ألسباب ثقافية واجتماعية في المنطقة .إن تطبيق برامج توعوية ووقائية تعتبر من أفضل
الوسائل التدبيرية الناجحة للحد من تزايد ظهور حاالت جديدة مثل تلك األمراض ،هذا باإلضافة
إلى توفيرالتشخيص المبكر لها .من أجل تحقيق نتائج مرغوب بها ،فإن من الواجب إيجاد
مسببات المرض على المستوى الجزيئي (عن طريق تحديد الطفرات والجينات المسببة
للمرض) .لذلك فإن الهدف من هذه الدراسة هو تحديد المسببات الجزيئية والخلوية لمجموعة من
األمراض المتنحية الموجودة بين مواطني وسكان دولة اإلمارات العربية المتحدة .لقد تم استخدام
تقنيات حديثه جدا مثل تقنيات ال ( )Whole Exome Sequencingباإلضافة إلى
( )Homozygosity Mappingو ) )Segregation Analysisعلى أفراد العائالت
المدروسة لدراسة وإيجاد الطفرات الجينية المسببة لتلك األمراض .الدراسات البيومعلوماتية ( In
 )Silico Bioinformaticsوالتجارب الوظيفية أيضا ً تم القيام بهما إلثبات وتأكيد طريقة
تطور المرض والكشف عن الميكانيكية الخلوية لها .نعلن في هذه األطروحة عن إيجاد طفرتين
مستحدثتين من نوع ( )Compound heterozygousفي جين يدعى ( )MPDZوالمسببة
الستسقاء في الدماغ ،هذا وقد تم إثبات ذلك مخبريا .باإلضافة لذلك ،نعلن عن إيجاد طفرة
مستحدثة في إنزيم يدعى ( )Xylosyltransferase Iوالمسؤول عن مرض ( Desbuquois
 ،)dysplasia IIكما ونزود أدلة عن تسبب جين ال ( )XYLT1في أسباب تطور هذا المرض
في طفرات أخرى في هذا الجين .نرشح أيضا في هذه الدراسة بعض الجينات التي قد تكون
مسببة لمتالزمة العجز الذهني ( )Intellectual disability syndromesعند عائلتين ،كما
ونقدم األدلة التمهيدية إلثباتها .في المجمل ،هذه األطروحة تقدم أدلة على الطرق المختلفة لتطور
المرض والطفرات المسببة لها .في المحصلة فإن هذا البحث سوف يفيد في المساعدة على

x

تشخيص مثل تلك األمراض وتطوير وتطبيق طرق وقائية على األقل ألفراد العائالت الممتدة
للمصابين.
مفاهيم البحث الرئيسية :األمراض الوراثية المتنحية ،)Desbuquois dysplasia( ،استسقاء
الدماغ الخلقي.(whole exome sequencing) ،(MPDZ) ،)1TLYX( ،
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Chapter 1: Introduction
1.1 United Arab Emirates: Country, Population and Demography
The United Arab Emirates (UAE) is a federal state established on the 2nd of
December, 1971 and is located in western Asia between 22°30' and 26°10' north
latitude and 51° and 56°25′ east longitude, with a total area of 83,600 km². It is a
constitutional federation consisting of seven emirates with Abu Dhabi as the largest
emirate where the capital (Abu Dhabi City) and the city of Al Ain are located. The
UAE is bordered by Oman from the east and south, Saudi Arabia from the west and
the Arabian Gulf from the north and east.
1.1.1 UAE Population and Society
The total population of the UAE was estimated at 9.38 million people in
2016, and is predicted to grow to 9.9 million by 2020. The current UAE population
is very diverse due to the high migration rates and is ranked 7th worldwide in the net
migration rate ("United Arab Emirates Population", 2017).
The population of the UAE is cosmopolitan which is attributed to the
migration from the Indian subcontinent, Asia, Baluchistan which lies southeasternmost edge of Iran, Pakistan, Oman and Afghanistan to the area (Quaife et al., 1994,
p. 42). South Asians comprise (58%) of the total residents, followed by other Asians
(17%) and western expatriates (8.5%) ("United Arab Emirates Population", 2017).
The UAE nationals constitute around 11% of the total population ("UAE Population
by Nationality", 2016).
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1.1.2 Consanguineous Marriages and Reproductive Health in UAE
The term consanguinity refers to marriage between blood relatives, the Latin
prefix “con” means “with” and “Sanguis” means “sense of blood”, and so the term
“consanguineous” is used to describe members who descend from the same ancestor
("Consanguineous", 2017). Medically, it is defined as the union between a couple
who is second cousins or closer. This union is measured by the inbreeding coefficient
(F) which is the probability of two alleles to be identical by descent (Leutenegger et
al., 2003), being equal or higher than 0.0156 (Bittles, 2001), that was conventionally
performed by counting the number of meiosis from loops in pedigrees. However, a
new method has been developed to estimate (F) by genome-wide marker maps
(Leutenegger, Sahbatou, Gazal, Cann, & Genin, 2011). Consanguinity is still a
preferred practice in the Arab world including UAE, exceeding 50% of all marriages
in some populations in the Middle East (Figure 1).

Figure 1: The global rate of consanguinity (Hamamy, 2012)
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In a study conducted in selected cities in UAE between 1994 and 1995, the
prevalence of consanguinity in UAE reached (50.0%) with inbreeding coefficient of
0.0222 (L. I. Al-Gazali et al., 1997), while the rate of consanguinity is less than
(0.5%) in the European population. Despite the increase of awareness of the health
risks of consanguinity, this practice is still prevalent in most Arab countries and it is
not even diminishing as a recent study of 600 Saudi women revealed (Warsy, AlJaser, Albdass, Al-Daihan, & Alanazi, 2014). In addition, it was observed that the
migration of communities practicing consanguinity to the western countries led to an
incremental rise in human inbreeding research. Although there are many conflicting
findings on the relation between consanguinity and general health such as fertility,
mortality and morbidity, it is agreed that it is a disadvantageous practice, in addition
to its clear link to higher rates of autosomal recessive disorders (ARDs) among
highly consanguineous populations (Bittles, 2001)
1.1.3 Autosomal Recessive Disorders (ADRs)
ARDs are diseases that run in families due to the transmission of a recessive
allele to offspring of carrier parents and that is manifested, in the majority of cases,
when the child is homozygous for the abnormal allele (Figure 2). ARDs are
monogenic disorders, the latter being categorized into dominant and X-linked and
recessive diseases. Although most monogenic disorders are rare individually, there
are millions of people worldwide affected by monogenic disorders and hence exert a
significant burden on population health ("World Health Organization", 2017). Highly
inbred communities encounter high numbers of ARDs, even the occurrence of two or
more ARDs have been often encountered within the same family in such
communities (Zlotogora, 1997). In principle, some autosomal recessive disease-
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causing alleles could be hidden for generations and are expressed upon
consanguineous marriages in subsequent generations (Jaouad et al., 2009).

Figure 2: Autosomal recessive pattern of inheritance. The affected child inherited
both recessive alleles from his heterozygous parents, while the carrier children, each
has inherited one normal allele from either parents and another mutated from the
other. The healthy sibling, on the other hand, received two copies of the wild type
allele from her parents (Lentz & Keats, 1993).
The number of genes to cause ARDs is steadily rising due to recent
discoveries and expected to reach several thousands. The number of genetic
conditions, including ARDs, with known molecular causes currently stands above
5000 (Figure 3).

Figure 3: The updated entries of Mendelian disorders (October 24th, 2017) (https://www.omim.org/statistics/entry)
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In a study attempted to generate whole exome variome on the Greater Middle
East (GME) region on 1,111 distant individuals, they detected large and rare (Runs
Of Homozygosity) (ROH) that would definitely assist in discovering more recessive
disease-causing genes, this database could be used as a source of human variants in
the Middle East and worldwide (Scott et al., 2016)
Furthermore, autosomal recessive disorders comprise the majority of many
diseases. For example, intellectual disability (ID) which exists in around 1% of the
world population is mostly inherited in an autosomal recessive pattern. In a study
which combined WES and homozygosity mapping, they were able to identify new
candidate genes implicated in autosomal recessive intellectual disability (ARID)
supported with transcriptional functional analyses (Harripaul et al., 2017)
On the other hand, regardless of the genotype-phenotype correlation and
pattern of inheritance in diseases, recessive inheritance identified in dominant
disorders should not be ignored as a study on Saudi families revealed. They
described 11 recessively inherited variants in genes previously and exclusively
implicated in dominant disorders. Intriguingly, they even observed new phenotypes
which revealed similar phenotypes in animal models knock-outs (Monies et al.,
2017).
1.1.4 Screening, Preventive Measures and Genetic Services
Screening strategies for genetic disorders include premarital, pre-conceptive,
neonatal, and population screening. The major aim behind these programs is to
reduce their occurrence and provide tools to diagnose them and ameliorate their
effects and possibly develop novel therapies. This could be done by promoting
preventive programs for the public and educating all community sectors starting from
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high school education and ending up with media, and that includes educating them
about the dangers of consanguinity (Teebi, 2010).
In UAE, the genetic services are still generally inadequate, taking place in
few centers across UAE, consultation is provided by a small number of clinical
geneticists, mainly providing counseling on thalassemia and sickle cell anemia as a
premarital testing. Moreover, those centers provide newborn screening for some
genetic condition such as phenylketonuria, congenital hypothyroidism and congenital
adrenal hyperplasia (L. Al-Gazali, Hamamy, & Al-Arrayad, 2006). This topic was
recently addressed in the genetic counseling workshop which took place at the 6th
Pan Arab Human Genetics Conferences (PAHGC) held in Dubai, UAE in 2016.
Encouraging the entities to take the responsibility in implementing counseling
programs and centers (Nair et al., 2016).
On one hand, the health authority in Abu Dhabi (HAAD) implemented the
newborn screening for the critical congenital heart diseases (CCHD), which has an
incidence of 8 per 1000 births in Abu Dhabi. This program resulted in the successful
detection of ten newborns suffering from CCHD and that led to adopting screening
programs on other diseases (Al Mazrouei, Moore, Ahmed, Mikula, & Martin, 2013).
On the other hand, pre-marital and pre-conception screening tests are not of
less importance due to the high prevalence of inherited disorders and carriers states
in UAE. For example, carrier frequencies of hemoglobinopathies such as βthalassemia and sickle cell anemia corresponded to 4.56% and 2.9%, respectively
from 6,420 Emirati screened individuals (Belhoul, Abdulrahman, & Alraei, 2013).
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Other congenital disorders such as congenital hypothyroidism (CH) were
expected to be due to genetic mutations in a study that took place in Abu Dhabi from
2011-2014. Genetic testing was performed on 10 out of 65 suspected patients and 3
patients were found to have mutations, one with a heterozygous mutation in thyroid
stimulating hormone receptor (TSHR) gene and two with homozygous mutations in
thyroid peroxidase (TPO) gene (Deeb et al., 2016).
1.2 Statement of the Problem
Despite significant efforts and discoveries on the underlying causes of many
monogenetic disorders in Arab countries and UAE, the rates of birth defects are still
unacceptably high in most Arab countries. For example, in the March of Dime 2006
report, the UAE was ranked sixth worldwide in terms of birth defects. It is believed
that 70% of birth defects’ effects could be prevented or decreased if diagnosed before
conception or at early stages of conception (The Catalogue for Transmission
Genetics in Arabs (CTGA) database (www.CAGS.org.ae). As indicated previously,
these high rates are most likely due to social tendencies as well as inadequate
preventative programs. For every 1000 live births in most Arab countries, 70-79 are
born with either physical or intellectual birth defects, for the UAE, 75.6 per 1000 live
births (March of Dimes report, 2006). That was closely attributed to the common
practice of consanguineous marriages, leading to high opportunities for combining of
recessive disease-causing alleles. Consanguinity in UAE exceeds half of all
marriages. Consequently, autosomal recessive disorders contribute to a high
proportion of genetic disorders and birth defects in UAE. Given the magnitude of the
burden of genetic diseases in UAE, the number of children born with birth defects
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can be potentially reduced by implementing more effective educational programs
including preventative interventions and accurate diagnostic provisions and tools.
According to experts in the human genetics field, the burden of genetic
disorders in UAE could be reduced considerably by implementing more effective
prevention programs. Genetic diseases are ranked fourth in terms of fatality in UAE.
Craig Venter described the high rates to be unusual. He added, that only when this
population’s genome is deciphered then changes could be made (Griffiths AJF,
2000).
Currently there are more than 400 genetic disorders described in UAE.
Although this number is normal in highly consanguineous communities, it is
considered a major public health problem in UAE. Therefore, our aim here is to
elucidate the genetic and cellular basis of rare inherited diseases in Emirati families
as well as UAE residents, pointing out the importance of studying those families,
hoping to provide tools for diagnosis that can be employed for more effective genetic
counselling and prevention programs, as well as mapping the causal genes and
mutations to build up and add more information to the body of scientific and medical
knowledge.
1.3 Objectives
•

Characterize Emirati families and expatriate residents of the UAE with
children affected by single gene disorders.

•

Perform homozygosity mapping on families affected by suspected autosomal
recessive single-gene disorders of unknown molecular cause, to identify the
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homozygous regions that are common among the genomes of affected
individuals.
•

Perform whole exome sequencing (WES) on selected affected individuals
from these families to identify candidate causative genes and variants.

•

Conduct Sanger DNA sequencing in candidate genes on those families to
confirm segregation of variants and narrow down or confirm the candidate
causative mutations.

•

Perform bioinformatics, in silico and functional analyses to confirm
pathogenicity and elucidate the pathogenesis mechanisms.

1.4 Relevant Literature
1.4.1 The Genetic Basics
Genetics is the branch of science concerned with heredity. Offspring inherit
genes from both parents, which will in turn be expressed into traits, disorders, or
disease risks. The vast majority of our genes are located within the 23 pairs of
chromosomes in a specific order. A copy of each of pair of chromosomes is inherited
from each parent and therefore a copy of each gene. Moreover, genes consist of
nucleotides linked in a very specific order. There are over 20,000 genes within the
human genome, which is defined as the whole set of DNA including all the genes of
an organism. DNA is made of four types of nucleotide bases (Adenine, Guanine,
Cytosine and Thymine, generally referred to as A, G, C, and T, respectively). There
are approximately 3.2 billion nucleotides making up the human genome (Bell et al.,
2011)
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The process of determining the complete sequence of the genome is called
whole genome sequencing (WGS). Although, it started as a research tool, WGS is
now employed routinely for diagnostic and therapeutic purposes. The idea of
sequencing the whole human genome was initially introduced in 1985 and formed
the first step towards the human genome project, launched officially in USA in 1990
and completed in 2003 (Venter, Smith, & Adams, 2015).
1.4.2 The Inherited Disorders
Inherited disorders are diseases that are passed down from parents to
offspring due to single gene mutation or chromosomal aberrations. Although most
single gene disorders are inherited in Mendelian patterns, phenotypes are not always
easily predicted. For example, in Gaucher disease (MIM 230800), there is no clear
correlation between the genetic mutation and the phenotypes of the patients (Sriram,
Martinez, McCabe, Liao, & Dipple, 2005). On the other hand, chromosomal
aberration refers to any change in the structure (e.g, translocations, duplication and
deletions) or number (Aneuploidy) of the chromosomes due to breaks or alterations
in the DNA (Bender, Griggs, & Bedford, 1974). Structural aberrations are mainly
caused following improper DNA repair, whereas numerical aberrations occur due to
segregation errors (non-disjunction) during cell division (Janssen, van der Burg,
Szuhai, Kops, & Medema, 2011). On the other hand, when genetic variations are
combined with environmental factors; that would increase the risk and may lead to
the development of multi-factorial disorders such as Schizophrenia, autism,
depression, type 2 diabetes. These disorders are often familial but they do not follow
the Mendelian patterns, rather, they can be explained by a continuous variable with a
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threshold above which individuals would show symptoms (Fraser, 1976). (Mitchell,
2012).
1.4.3 Overview of the Diagnostic Approach in Genetic Conditions
Mutation detection using DNA sequencing is becoming an essential
component of the diagnosis of genetic diseases. It can be carried out at the prenatal,
premarital, pre-implantation periods and used for diagnostic purposes (Cotton, 1993).
Methods of detection of single gene mutations could be performed by direct
sequencing of the DNA or RNA using different PCR techniques and microarrays
(Mahdieh & Rabbani, 2013), or indirectly in linkage study analyses using Short
tandem repeats (STRs) or single nucleotide polymorphisms (SNPs) markers.
NGS has become an essential tool in disease gene discovery and diagnosis; it
refers to any high-throughput, cost effective technologies. These technologies can be
applied in WGS, WES, transcriptome sequencing, chromatin immunoprecipitation
(ChIP) sequencing, epigenome characterization, etc. Although mutations in exons
cover 85% of the Mendelian disorders, a significant number of potentially harmful
variants, within non-coding regions for example, could be left undetected by WES,
hence, WGS is favorable in some cases, especially when WES fails to reveal the
causative mutation (Mahdieh & Rabbani, 2013). Additionally, there are several other
approaches to identify mutations by direct DNA re-sequencing.
Transcriptome sequencing on the other hand, provides insights on the
expression levels of genes in cells in a real-time fashion by generating libraries
through fragmentation, ligation, and sequencing, also called RNA sequencing, being
more sensitive than microarrays in identifying splice-variants and non-coding RNAs.
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Moreover,

ChIP

sequencing

allows

the

fragmentation

and

immunoprecipitation of DNA-associated proteins and sequencing the DNA after
hybridizing it on a chip (ChIP-Chip microarray) (de Magalhaes, Finch, & Janssens,
2010).
On the other hand, chromosomal abnormalities can be identified by
cytogenetic

methods

using

conventional

karyotyping,

fluorescent

in

situ

hybridization (FISH), comparative genomic hybridization (CGH) or microarrays
(Riegel, 2014). The overall approach of diagnosis also involves physical
examination, biochemical or cytogenetic testing in some diseases.
1.4.3.1 Physical Examination
The main objective of medical geneticists is to describe the cause of birth
defects or developmental abnormalities in children or adults. Although it seems
similar to the general medical examination, physical examination however in these
cases aims to closely examine any deviations in development from normal. One of
the major factors which could help in diagnosis is the occurrence of a phenotype in
family history, either in live or still births. Moreover, the presence of dysmorphic
features, intellectual disabilities and developmental delay are highly suggestive of
genetic disorders (Best, Rosser, & Bajaj, 2017). Despite the fact that most genetic
disorders are presented during childhood, such disorders should not be overlooked if
they show up in adulthood ("Genetic Alliance; The New York-Mid-Atlantic
Consortium for Genetic and Newborn Screening Services", 2009).
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1.4.3.2 Biochemical Testing
Changes in protein levels and/or activity may be due to a mutation in the
gene’s DNA sequence. In cases of biochemical enzymes, this often results in a
genetic disorder belonging to the so called “inborn errors of metabolism”. This group
of genetic disorders include fatty acid oxidation disorders, organic acidurias,
aminoacidopathies and others (Schiff, 2017). Measuring body fluids’ changes of
such enzymes and/or their metabolites may help in their diagnosis (Sandlers, 2017).
Currently, tandem mass spectrometry allows for measuring more than 20
biochemical genetic disorders by looking at the levels of their metabolites. However,
expanded newborn screening tests have raised a major concern of false positive
results due to child-parental anxiety rather than laboratory errors. These concerns can
be overcome by educating parents prior to testing in order to benefit from the
positive impact of such tests on the well-being of the affected infants (Holtzman,
2004).
1.4.3.3 Cytogenetics
Cytogenetics is a field of genetics concerned with the analysis of the numbers
and structures of chromosomes and consequences related to their abnormalities.
Chromosomes for cytogenetic testing could be obtained from several sources such as
peripheral blood, fetal blood, oocytes, spermatozoa, and others. Assessment of the
integrity of chromosomes is carried out through karyotyping. Since 1960s diagnostic
cytogenetics has evolved, allowing DNA and RNA probes to recognize genetic
sequences using different techniques (Trask, 2002). Cytogenetic microarrays are
becoming crucial tools in clinical use for the diagnosis of chromosomal
abnormalities. In the array comparative genomic hybridization (CGH), copy number
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variants (CNVs) are determined in patients compared to controls. Although
microarray is a robust technique for CNVs, it should not always be the first option
due to the long turn-around time. For example, karyotyping is more useful in
aneuploidies, and fluorescent in situ hybridization technique (FISH) is more
appropriate in diagnosing a well-described syndromes such as Williams and De
George syndromes (Manning & Hudgins, 2010).
1.4.3.4 Molecular Analysis
The human diploid cell is composed of nearly 6 billion base pairs making up
the 23 pairs of chromosomes, in addition to the mitochondrial genome which codes
for 37 genes only. Genomic variation exists among individuals and population
causing differences at the DNA level that can be inherited among offspring. If these
variations result in a disordered state, they are termed ‘mutations’. Whereas, nondeleterious variations are termed ‘polymorphisms’ (Javed, Huang, & Bombard,
1995).
Molecular analysis is an approach which is concerned with the analysis of
DNA, RNA or proteins in some cases. There are direct and indirect molecular
methods to this approach. The direct method is most applicable when the causative
gene of a particular disease is known. Hemoglobinopathies are the best examples of
such diseases. Direct DNA sequencing and the use of restriction enzyme digestion
are examples on direct analyses. For example, restriction fragment length
polymorphism (RFLP) detects differences between DNA sequences after applying
restriction endonucleases, followed by hybridizing the fragments with labeled probe
and running it in gel electrophoresis (Lander & Botstein, 1989). Indirect methods, on
the other hand, are applied when a disorder exists in a family of unknown genetic
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causes, in such cases linkage studies using polymorphic DNA markers closely
related to the disease-causing genes such as short tandem repeats (STRs) or SNPs,
are the most appropriate choices (Javed et al., 1995).
1.4.3.5 Next Generation Sequencing (NGS)
DNA sequencing had undergone unprecedented rapid and significant
developments over the last few years allowing the human genome, for example, to be
sequenced in a few days for around USD 1000 (Petersen, Fredrich, Hoeppner,
Ellinghaus, & Franke, 2017). Efforts to develop methods for DNA sequencing
started in the early 1970s with Gilbert and Maxam in 1973 using wandering-spot
analysis (Maxam & Gilbert, 1980). A few years later Fredrick Sanger developed a
novel methodology using chain-terminating dideoxynucleotides, now known as
Sanger Sequencing. Although it was used for the human genome sequencing project,
due to its long turn-around time this method is unsuitable for large-scale sequencing
projects that involves the sequencing of whole genomes of large number of
individuals. Therefore, efforts to speed up sequencing at reduced costs were intensive
globally which resulted in the development of the first next generation sequencing
instrument around the mid-2000s (Venter et al., 2015).
The next step-forward in NGS was the introduction of enrichment methods
by designing probes that could select DNA fragments, such as extracting exons in
whole exome sequencing (WES) (Petersen et al., 2017).
All the different types of NGS platforms do sequencing to millions of DNA
fragments in parallel. Moreover, these fragments are sequenced multiple times to
reach high depth sequencing for more reliable data in a short period of time.
However, limitations of these approaches centralize on the need for the
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comprehensive bioinformatics expertise to analyze and interpret the NGS data. In
addition, there is a need for the use of high storage capacity computers and
sophisticated IT set ups (Behjati & Tarpey, 2013).
1.4.4 Tools for Genetic Analysis
1.4.4.1 Bioinformatics and Computational Analysis
Genomic technologies generate remarkable amounts of genetic data that
requires soft-wares and tools for their analysis and storage. Bioinformatics is the
branch involving both computing and biology concerned with this process. For
example, scientists use computational analysis of genes to identify their functions for
diagnostic and sometimes therapeutic purposes. In the case of NGS, bioinformatics
tools are employed for mutation prediction, gene expression, gene regulation and
many other applications (Lindblom & Robinson, 2011).
Computational analyses are applied in multi-disciplinary fields in genetics,
for example, aligning DNA or amino acid sequences among different species is
performed daily using Basic Local Alignment Search Tool (BLAST) algorithms
(Benson, Karsch-Mizrachi, Lipman, Ostell, & Wheeler, 2008). Additionally, genome
wide associations studies (GWAS) performed to identify variants as risk factors
predictors associated with different diseases, especially multifactorial conditions,
have used robust bioinformatics tools to integrate data from different data bases such
as Human Genome Research institute (NHGRI) and SNAP (SNP Annotation and
Proxy Search) (Yu et al., 2011).
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1.4.4.2 Whole Exome Sequencing (WES)
WES is a robust, reproducible method that sequences most targeted proteincoding regions on the DNA to identify changes in the human genome in patients with
genetic disorders. Several WES platforms have been developed, in principle,
solution-based WES involves DNA shearing, labelling and hybridizing to
oligonucleotide probes bound to magnetic beads, washing away the unbound,
followed by PCR for enrichment and sequencing. The same applies on array-based
methods except for capturing probes on a microarray chip (Warr et al., 2015).
The first story of success of using WES for the diagnosis of single gene
disorders was back in 2010 with three individuals suffering from Miller syndrome
(Ng et al., 2010). Henceforth, WES has been extensively applied to detect novel
mutations (Worthey et al., 2011) and currently employed in routine use in most
developed molecular diagnostic genetic laboratories (Valencia et al., 2015).
WES is also useful in the diagnosis of early, incomplete spectrum of
symptoms and in prenatal diagnosis (Iglesias et al., 2014) allowing for a confirmed
diagnosis and prognosis, finding better treatment and avoiding unnecessary invasive
procedures to the patients (Warr et al., 2015).
Despite the fact that whole genome sequencing is becoming more affordable
due to the drop in sequencing costs, WES is still the cheaper choice, so it remains a
suitable tool when combined with powerful statistical approaches. Additionally,
whole genome sequencing is hampered by the need of huge storing and data analysis
technologies that have not accelerated as sequencing technologies have (Sboner, Mu,
Greenbaum, Auerbach, & Gerstein, 2011).
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WES has been lately combined with other strategies such as linkage analysis
and homozygosity mapping in the filtration process to identify novel variants in
consanguineous families affected by autosomal recessive disorders (T. Guo et al.,
2017), among which, compound heterozygous mutations and copy number variations
(CNVs) are common. However, WES remains a challenging procedure to identify
CNVs, making other suitable analytical methods needed such as array platforms and
quantitative real-time PCR (qPCR) (Li & Olivier, 2013).
1.4.4.3 Sanger Sequencing
Sanger method was developed by Fredrick Sanger in the late 1970 and is a
procedure to determine the DNA sequence using (DNA polymerase I) which
incorporates radiolabelled triphosphates into the 3’ end of a primer polynucleotide
and extended complementarily in four separate reactions, synthesis would proceed
until the incorporation of a di-deoxyribotriphosphate leading to a termination of the
reaction. Later in 1986 an automated Sanger sequencing method was developed by
attaching different colored fluorophores to the four nucleotide bases and the mixture
electrophoresed in a single gel tube. Subsequently, the fluorescent bands were
analyzed by a computer’s software (Figure 4) (Smith et al., 1986). In 1987 Applied
Biosystems introduced the first machine called AB370, detecting 600 bases read
length. In 1995, the model AB3730xl reached a read length of 900 bases. In 1998,
the upgraded automated Sanger machine was used in the human genome project.
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Figure 4: Sanger sequencing by chain-terminating di-deoxynucleotides
(http://www.vce.bioninja.com.au/)
1.4.4.4 Homozygosity Mapping
It is well established that consanguinity increases the chances of acquiring
genetic disorders due to the increase in the percentage of the genome that is identical
by descent. Relatedness can be measured by the inbreeding coefficient (F), ranging
from third cousin to double first cousin marriages (F=>0.4-12.5%). Disease-causing
genes often reside in blocks of homozygosities passed to progeny (Alkuraya, 2010),
and in the case of rare autosomal disorders, the probability of having homozygous
mutations is higher than the state of compound heterozygous mutations (Aldahmesh
et al., 2009). Therefore, it is much easier to scan disease-causing genes within the
homozygous regions among consanguineous families than in outbred ones, where
researchers rely on the candidacy of high frequently involved genes (Alkuraya,
2010).
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Homozygosity mapping is a robust technique which identifies homozygous
regions on the chromosomes using SNP genotyping arrays. For example, the
genome-wide human SNP array 6.0 can detect more than 900,000 SNPs. For
homozygoisty mapping, the genomic DNA is digested using restriction enzymes
(REs) and ligated to adaptors that can be recognized by generic primers for
amplification. Subsequently, all amplicons will be fragmented, labelled, and then
hybridized to the microarray chip (Figure 5).

Figure 5: Illustration of the human genome wide SNP genotyping array 6.0
(http://www.seoulin.co.kr/)
Homozygosity mapping is considered a powerful technique in the
identification of heterogeneous ARDs in highly consanguineous populations. For
example, in seven Saudi families suffering from Bardet-Biedl syndrome with poor
genotypic-phenotypic correlation where conventional direct DNA sequencing of the
candidate genes missed some of the identified mutations due to their presence in
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novel deep intronic regions which resulted in splice-site mutations (Abu Safieh et al.,
2010).
1.4.4.5 Variants Filtering Techniques
The vast amount of data generated from WES requires significant
bioinformatics analyses in order to identify the causative mutations and genes.
Filtration techniques can be automated or manually performed, but dependence on
automation alone could lead to finding some false positives or elimination of relevant
candidate variants (Jalali Sefid Dashti & Gamieldien, 2017).
Filtration of variants highly depends on bioinformatics tools to predict their
effect on the protein function. However, analysts should carefully estimate the
validity of such predictions, recent studies have shown that half the ‘predicted’
deleterious variants turned out to be neutral (Miosge et al., 2015). It is thus advisable,
according to published guidelines, to combine several protein prediction tools during
filtration such as SIFT (sorting intolerant from tolerant), PolyPhen (Polymorphism
Phenotyping) (Sim et al., 2012), (Adzhubei et al., 2010), Mutation Taster, FATHMM
(Functional Analysis Through Hidden Markov Models), and others to increase the
prediction specificity (Jalali Sefid Dashti & Gamieldien, 2017). Additional tools for
analyzing domains of translated proteins and the positioning of the variants within is
a supportive step to be performed in the filtering pipeline. One of the classical,
diagnostic

and

powerful

tools

is

the

InterProScan

database

(www.ebi.

Ac.uk/interpro/search/sequence-search).
During filtration it is advisable to look into Ensembl transcripts rather than
reference sequences (RefSeq), since it was shown by McCarthy and his colleagues
that a large number of damaging variants were lost when using RefSeq only and that
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there was 44% agreement in annotations between RefSeq and Ensembl transcripts
leading to the dismissal of interesting and perhaps relevant variants (McCarthy et al.,
2014).
Potential consequences of variants such as missense, splice-site and nonsense
are highly considerable compared to the intronic and synonymous ones assuming
they have no functional impact. Additionally, conservation of the sequenced variants
among species as well as the population frequencies of filtered variants are
paramount criteria because the rarity of the variant has a greater attribution to the
disease than the recurrently occurring ones, the most frequently studied is the minor
allelic frequency (MAF) which is favorable to be the starting point in any filtering
study. Allelic frequency data can be retrieved from multiple sources, some of the
most widely used are from Ensembl (http://asia.ensembl.org/), ExAC browsers
(Exome Aggregation Consortium) (http://exac.broadinstitute.org/), and the Exome
Variant Server (evs.gs.washington.edu/).
Furthermore, candidate genes can be filtered based on relevant clinical
phenotypes assisted by robust databases like OMIM (Online Mendelian Inheritance
in Man) (http://www.omim.org/) and Gene Distiller (www. Genedistiller.org). The
Human Gene Mutation Database (HGMD) also simplifies filtration through
collecting all the published mutations and related inherited diseases (http://www.
hgmd.org).
As stated earlier, there is no single and unified pipeline to use for filtration
since all have limitations and drawbacks. Generally, if a variant achieves most of the
pipeline criteria, then it is expected to have genotype-phenotype correlation, however
this should not always be the case to determine its candidacy (Jalali Sefid Dashti &
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Gamieldien, 2017). Figure 6 illustrates the general filtering pipeline I followed in my
study.

Figure 6: Designed guide for the filtering and prioritizing of variants

1.4.5 Major Cellular Mechanisms of Genetic Diseases
1.4.5.1 Loss of Function versus Gain of Function
Mutations in genes could either lead to losing the native function of the
protein (loss-of-function, LoF) or acquiring a new function to the protein (gain-offunction, GoF). For example, in some enzymes mutations could lead to losing the
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catalytic domain (LoF) such as mutations in fumarate hydratase enzyme,
predisposing individuals to multiple cutaneous and uterine leiomyomatosis (MCUL)
(Alam, Olpin, & Leigh, 2005), or they could lead to gaining a new enzymatic activity
like mutations in isocitrate dehydrogenase in human gliomas (Guo, Pirozzi, Lopez, &
Yan, 2011). On the other hand, different mutations on the same gene could lead to
different phenotypes, for example in FGFR1 gene, LoF mutations result in
craniosynostosis, whereas GoF mutations cause Kallmann syndrome. There are some
features that could distinguish LoF and GoF mutations with statistical accuracy
levels of around 70%. Jung S. and his colleagues found that the mutation type, the
substituted allele, the functional effect of the mutation and the domain affected are
among the features determining LoFs and GoFs (Jung, Lee, Kim, & Nam, 2015).
Since most ARDs, the subject of this dissertation, are caused by LoF mutations, the
following sections will deal with the major LoF mechanisms.
1.4.5.2 Nonesense Mediated Decay (NMD) and Destabilization of the mRNA
NMD refers to the degradation of mRNA due to carrying a pre-mature stop
codon mutation. Decay occurs after introns splicing, in their way to produce the
mature mRNA. Naturally, around 30% of mRNA splice variants undergo NMD,
splicing occurs on consensus sequences by splicesomes. Some studies attributed the
physiological levels of mRNA to NMD processes, that’s why NMD is a crucial
mechanism in the nervous system to maintain the levels of gene expression in cells
that would otherwise lead to neurological disorders (da Costa, Menezes, & Romao,
2017).
NMD is essential in preventing the dominant negative effects of the nonfunctional proteins as well as the aggregation of misfolded ones. However, there is a
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growing evidence that NMD could alternatively be harmful due to the lack of protein
synthesis which might retain some residual activity. In some diseases the NMD
mechanism gives milder phenotypes due to haploinsufficiency such as mutations in
SOX10

gene

in

Waardinburg

disease

or

in

LDLR

causing

familial

hypercholesterolemia, while in other cases, the synthesis of the mutated protein leads
to dominant negative effect like nonsense mutations in SOX10 gene leading to severe
phenotypes (Inoue et al., 2007).
1.4.5.3 Protein Mis-folding, Mis-localization and Prevention of Posttranslational
Modifications
After their synthesis on ribosomes, proteins need to fold and often must get
modified and assemble into complexes before they can perform their biological
function, and secretory pathway targeted proteins are no exception. The endoplasmic
reticulum (ER) is the entry point organelle of the secretory pathway and is
responsible for many cellular processes including protein folding, assembly and
secretion. About one third of translated proteins are targeted to the ER (Powers &
Walter, 1997), where their final destination is determined to different post-ER
compartments via a signal peptide of 20-30 amino acids in length (Johnson & van
Waes, 1999). They also get folded during translational process, but the major folding
occurs in the ER lumen where the signal peptide is cleaved influencing proper
folding. Post-translational modifications such as disulfide bonds, acetylation,
glycosylation, and biotinylation are crucial for folding (Helenius & Aebi, 2001).
Additionally, molecular chaperones like the heat shock proteins, calnexin, and thioloxidoreductases are the gate-keepers for protein folding, they function by lowering
the free-energy barriers and the formation of aberrant molecules (Nishikawa,
Brodsky, & Nakatsukasa, 2005).
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If a protein is misfolded, it will be either; refolded, degraded or sequestered.
Misfolded proteins are recognized by different ER molecular chaperones that help
their retention, targeting them for further folding. Folding becomes inefficient when
the total protein concentrations reach high amounts, taking several hours (Kleizen &
Braakman, 2004). The ER quality control machinery will tag them for degradation
via the ubiquitin proteasome system (UPS). For most proteins, the proper threedimensional protein structure is determined by its primary sequence. Thus, mutations
in the amino acid sequence might cause inappropriate folding pathways, leading to
the formation of misfolded proteins that will be often returned to the cytoplasm to be
degraded (Figure 7). Impairments in such quality control systems could lead to
aggregation of misfolded proteins in cells as amyloid-like structures, such as the
cases in neurodegenerative disorders (Chaudhuri & Paul, 2006).

Figure 7: Protein folding (Nature Education 2010)
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On the other hand, sequestration is important to contain toxic proteins away
from the cellular environment and to enhance asymmetric inheritance of the damaged
proteins (Sontag, Samant, & Frydman, 2017). There are multiple mechanisms in
protein mis-folding, such as loss of function mutations as in cystic fibrosis, rendering
the proteins unstable and prone to degradation, and in α1-antitrypsin deficiency, the
protein is continuously degraded by UPS, thus its deficiency in its specific site
causes the disease to occur. On the other hand, Alzheimer’s disease occurs by a gainof-function mechanism that results from accumulating fibrillary amyloid deposits
(Chaudhuri & Paul, 2006).
When proteins are fully synthesized and folded they should traffic and get
targeted to their final destination either inside the cellular organelles or
extracellularly where they perform their proper function. Mislocaliztion could be
attributed to loss of localization signals, for example loss of nuclear signal in sex
determining region Y protein (SRY) is responsible for Swyer syndrome (McLane &
Corbett, 2009).
Others could be due to aberrant folding of proteins. For example, in Robinow
syndrome all missense mutations had been responsible for the loss of function in the
frizzled-like cysteine rich domain and kringle domain of one of the tyrosine kinase
receptor members (ROR2) leading to misfolding and retention in the ER (Ali et al.,
2007). Additionally, defects in cargo proteins could as well be a reason for
mislocalization, as in rhizomelic chondrodysplasia punctata type 1, resulting from a
mutation in PEX7 gene which encodes peroxisomal matrix import receptor
(Braverman et al., 1997).
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1.4.5.4 Loss of Active Site or Significant Functional Residue
Amino acid sequences of enzymes that are involved in the catalytic domain
or in the substrate binding pockets, or can at least support the configuration of the
active site are highly conserved in proteins. Mutations in such locations could lead to
either reduced or complete loss of their function (Porter, Bartlett, & Thornton, 2004).
For

example,

certain

mutations

in

phenylalanine

hydroxylase

causing

phenylketonuria occur at the catalytic sites, inducing structural changes in the active
domain causing PAH enzyme deficiency (Gersting et al., 2008).
Moreover, mutations affecting essential domains of proteins might affect
their stability and function. For example, missense mutations occurring at domains
16–17 of Filamin A gene (FLNA) known to cause Larsen syndrome and
Frontometaphyseal dysplasia were studied by combining crystallography and
simulation techniques on the protein’s structure, they found that mutations in those
domains converted its structure from compact to elongated causing destabilization of
the protein (Seppala et al., 2017)
1.4.5.5 Disruption of Gene Expression
Intronic mutations could affect the regulatory sites of a gene and hence,
disrupt its expression either by introducing or eliminating an enhancer’s or a
suppressor’s activity. Moreover, mutations introducing cryptic splice-sites could alter
mRNA expression by affecting its stability, by deleting or inserting new regulatory
elements or generating a truncated protein, for example, the decreased levels of
mRNA and protein expressions of the myotonin-protein kinase gene have been
associated with myotonic dystrophy (Fu et al., 1993). In some cases, the expression
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of alternative splice-variants could cause a disease state if the gene is expressed in an
improper tissue or developmental stage (Faustino & Cooper, 2003).
Furthermore, point mutations affecting RNA polymerase binding sites, or the
translation-initiation sites, would potentially alter gene expression in tissues
(Griffiths AJF, 2000).
1.5 Rationale for this Study
Congenital and genetic disorders are responsible for the majority of morbidity
and mortality in UAE and the Arab world due to high consanguinity rates. This
burden is increased due to the lack of preventative health measures. In addition, in
single gene disorders, which have high prevalence in such communities, there isn’t
always a direct and obvious correlation between genotypes and phenotypes.
Therefore, studying the molecular and cellular functions through experimental
approaches and Bioinformatics is crucial to elucidate the causal factors in some
inherited diseases. Designing correct experiments, under which rational hypotheses
stand, as well as interpretation of their results could provide accurate methods in
identifying novel mutations or in discovering novel genes, consequently expanding
the genotypic spectrum of genetic diseases and elucidate their pathogenesis. These
findings could have a crucial impact on having accurate diagnostic tools,
development of effective prevention programs and possibly improving management
of these conditions.
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1.6 Potential Contributions and Limitations of the Study
1.6.1 Limitations


Blood samples as well as fibroblasts were obtained, when possible, during the
field work. Nevertheless, there were some difficulties in getting samples from
some families either due to inaccessibility of the relevant tissue such as in the
case of neuronal cells or due to non-collaborating members from the affected
family. Therefore, mammalian expression plasmid constructs were developed
and expressed in cultured cell lines as an alternative, in an attempt to evaluate
the potential effects of the identified variants.



Lack of treatment options for most genetics conditions raised a challenge
because parents of affected children often feel angry and/or frustrated in such
cases and some of them therefore might be unwilling to fully cooperate.



In WES analysis, data often contain variants of uncertain significance (VUS),
these variants cannot be neglected but require significant efforts to provide
evidence of their pathogenicity or not. For example, in a case of intronic VUS in
FTO gene (Fat mass and Obesity-associated protein) detected by GWAS, the
variant was erroneously thought to affect FTO gene regulation, but turned out to
affect distantly IRX3 gene (Iroquois-class homeodomain protein) (Smemo et al.,
2014).



During the filtration process of the WES data, regions outside the protein coding
and splice sites sequences could not be evaluated despite their importance in
regulating gene expression, although not a general feature.



Gene discovery sometimes requires acceptable sample size of affected
individuals as well as patients from several families exhibiting the same
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phenotype in order to increase the power of the study. Unfortunately, it was not
always feasible to find such criteria in multiple unconnected families due to the
rarity of the studied disorders.


The studied families exhibit variable phenotypes, which was due to the nature of
the families that were evaluated at Tawam Genetics unit. This unit is the major
referral genetics center in UAE and supports patients with all kinds of genetic
conditions from various parts of the country as well as the expatriate
populations.

1.6.2 Contributions


The advent of novel mutations presented in the current study is important to
comprehend the pathogenesis and mechanisms by which the studied genetic
disorders occur. In addition to its contribution to the diagnostic approach for
patients affected with similar disorders, and that includes different categories,
such as pre-conception, prenatal, neonatal, as well as late onset of the diseases in
adult life.



Exploiting molecular approaches to identify novel candidate genes responsible
for monogenic disorders and if proved, to determine the mechanisms by which
they cause the phenotypes.



Defining strategies for population screening who are highly at risk, such as
communities with highly in-bred families who would most probably host large
numbers of carriers of genetic mutations. This category can be screened for
known mutations and identified as carriers, with aim to limit further
implications, especially among members of their extended families who might
be as well carrying the same mutations.
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Genetic research contributes to genetic counseling which has a great impact on
risk perception, albeit, counseling should be conducted on a wider variety of
hereditary disorders.



Defining future strategies in management and treatment for the genetic
disorders.
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Chapter 2: Methods
2.1 Purpose of the Study
This study was designed to establish and/or confirm the pathogenesis of
disease-causing mutations in genes underlying autosomal recessive disorders in UAE
and to understand the mechanisms by which these mutations may cause the
phenotypes.
The approach in this dissertation is a mixture of experimental and qualitative
approaches, planned to prove the main hypothesis which states that autosomal
recessive single-gene disorders are most likely caused by biallelic loss-of-function
mutations in the underlying genes within the genomes of the affected individuals.
This is a phenomenological study focusing on ideographic cases to
understand and explain the participants’ disease states.
2.2 Research Design
2.2.1 Settings and Participants
This study took place in Al Ain city within the emirate of Abu Dhabi, part of
the UAE confederation. The participants were recruited from Tawam hospital (Al
Ain) through Prof. Lihadh Al-Gazali. The affected individuals are from the pediatric
category suffering from different autosomal recessive disorders.
It is generally accepted that the number of samples is determined by the type
of the study. In rare diseases, the number of samples required is much smaller than
other diseases. In our study, one of the diseases has a prevalence as low as <1 in
1,000,000 individuals. Moreover, some rare diseases show geographical variations in
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prevalence. Although it is always favorable to have larger number of samples from
unrelated families in the gene discovery for rare diseases, that is often not possible
due to their rarity, and current technologies may allow gene discovery in one or two
families, even in a single case in some situations. For example, in Kabuki syndrome
only 10 patients were sequenced to identify 7 de novo variants in MLL2 gene
(MacArthur et al., 2014).
In summary, this investigation is open and flexible to more cases if available,
thus, accumulating more cases suffering from the same genetic disorder will assist in
a more comparative analysis and provide support to our findings, which is referred to
as discriminate sampling.
2.2.2 Sampling Techniques
Bio-samples collected for this study were mainly blood and fibroblast cells
from affected and non-affected family members, when available. Whole blood
samples were collected at Tawam Hospital in the city of Al-Ain in anti-coagulant
treated tubes (ethylenediamine tetra acetic acid, EDTA) with lavender tops for DNA
and RNA extractions. In some cases, fibroblast cells were collected by skin punch
biopsy from patients’ skin and kept in 20% Dulbecco's Modified Eagle Medium
(DMEM) and sent directly to our laboratory for processing and culturing.
2.2.3 Permission and Consent Forms
Informed written consents were obtained from the parents of all the recruited
affected minors. The risks to the participating families is minimal and blood samples
often collected as part of their routine workup, and in any case the magnitude of
discomfort did not exceed the one encountered in daily life, neither physically nor
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psychologically. Written consents for publications, where required, were also
obtained from the parents.
2.2.4 Ethical Considerations
This study was approved by Al-Ain District Medical Human Research Ethics
Committee (AAMD/HREC 10/09 and ERH-2015-3241 15-115). The study presented
minimal risk to all participants and the procedures were fully explained to them.
Information sheet about the study in both Arabic and English languages were
provided to the families. Confidentiality was consigned from the initiation of the
research work to the release of the results in the form of scientific publications.
2.3 Details of Techniques and Methodologies Used
2.3.1 DNA Extraction
2.3.1.1 DNA Extraction from White Blood Cells
Genomic DNA was purified from peripheral blood leukocytes following the
Flexigene DNA extraction kit protocols (Qiagen. Gmbh, Germany). The protocol
starts by lysing cells with the provided lysis buffer (FG1), then centrifugation of the
sample and discarding the supernatant, this could be repeated until major cell debris
and some contaminants are washed away completely. A master mix of protease and
lysis buffer 2 (FG2) was prepared and added then the mixture was incubated at 65 ºC
for 5 minutes to digest the contaminating proteins. DNA was then precipitated by
adding 100% iso-propanol, and the pellet washed further with 70% ethanol. To
dissolve the DNA pellet, the provided buffer 3 (FG3) was added and incubated at 65
ºC for 1 hour to dissolve the DNA into the aqueous solution. DNA concentration and
purities were measured by Nanodrop Spectrophotometer 1000 (ND-1000; Thermo
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Fisher Scientific, USA), the absorbance of DNA/protein (A260/280) with good DNA
quality sample should be around 1.8 A260/280, and DNA to salts purity (A260/230)
should be more than 2.5.
2.3.1.2 DNA Extraction from Gel
The protocol used was the described and provided by the manufacturer for
the MinElute Gel Extraction Kit (Qiagen. Gmbh, Germany), which aims to extract
DNA fragments from gel by excising the fragment of interest under the UV light,
using a sterile scalpel. After measuring the Eppendorf tube weight before and after
the inclusion of the gel, 3 volumes of buffer QG were added to one volume of gel
and incubated at 50 ºC for 10 minutes or until dissolved. Then one volume of isopropanol was added and mixed by inversion. The sample was then applied to
MinElute column fixed on the vacuum manifold until all liquid had passed. 500 µl of
buffer QG was added under vacuum, followed by 750 µl of PE buffer. The columns
were placed in clean 1.5 ml microcentrifuge tubes and DNA was collected after
adding 10 µl of EB buffer to the center of the membrane, let stand for 1 minute and
DNA collected by centrifugation.
2.3.2 RNA Extraction
Total RNA was extracted from whole blood using SV Total RNA Isolation
system (Promega, USA). This method provides a fast and simple way of isolating
total RNA from blood and tissues. Briefly, blood collected in EDTA-treated tubes
was lysed with buffer 1 (FG1) from the kit and the supernatant discarded in the same
way mentioned earlier for DNA extraction. However, RNA lysis buffer was added
here and incubated in ice for 15 minutes. Then RNA dilution buffer was then added
and heated at 70 ºC for 3 minutes. The lysate was collected after centrifugation and
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95% ethanol added to precipitate the RNA, transferred to a column and washed with
RNA wash buffer. To reduce genomic DNA contamination, DNAase I was added,
followed by RNA washing then elution. For a good quality RNA, the 260/280 ratio
should range between 1.8 and 2.2. In cases of extracting RNA from cultured cells,
cells were detached, washed with 1x phosphate buffered saline (PBS), pelleted and
RNA lysis buffer added and method performed as described above.
2.3.3 Protein Extraction from Cultured Cells
Forty-eight hours post-transfection, either HEK293T or HeLa cells were
scraped and washed twice with ice-cold PBS. To the cell pellets, 200 μl of ice-cold
RIPA lysis and extraction buffer (Thermo Fisher Scientific, Waltham, MA) was
added. In case of extracting nuclear proteins for co-immunoprecipitation studies
(CO-IP), 1% in-house Triton X-100 was used with 10% of protease inhibitor cocktail
(SigmaFAST Protease Inhibitor Cocktail Tablets, EDTA-Free; Sigma S8830) then
incubated at 4 ºC on a rotator for 1 hr. For CO-IP, the lysate was sonicated at 20%
power for 10 seconds in Sonic Ruptor homogenizer (www.Omni-inc.com), then the
extracts were centrifuged at 4 °C on 14,000 x g for 20 minutes. Supernatants
containing the extracted proteins were then transferred into fresh 0.5 ml tubes and
kept at -80 ºC.
2.3.4 Protein Concentration from Cultured Cells Media
Extracellular secreted proteins were collected and concentrated from the
supernatants of cultured cells using Amicon Ultra-15 Centrifugal Filter Devices
(Merck Millipore Ltd, Ireland). These devices have the capability of retaining and
concentrating proteins according to their molecular weight. The tubes selected for
our assay were of 30 K molecular weight cut-off (MWCO) to recover a protein of 60
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kDa. Each tube can hold 15 ml of media collected from the cultured cells wells, spun
at 4,000 x g for 20 minutes. Subsequently, the concentrated solute was recovered
from the filter device using a pipette as instructed.
2.3.5 Protein Concentration Determination
Total protein can be assayed colorimetrically using Pierce™ BCA Protein
Assay Kit (Thermo Fisher Scientific, Waltham, MA) by chelating copper ions with
protein in an alkaline solution forming a light blue complex, measured by
spectrometer. The standard protocol described in the manufacturer’s instructions was
strictly followed. Standard curves are drawn using absorbance values of standards of
bovine serum albumin (BSA) to calculate protein concentration.
2.3.6 Co-Immunoprecipitation of Proteins
Co-immunoprecipitation (CO-IP) is one of the widely used techniques to
detect protein-protein interactions using specific antibodies to indirectly capture
bound proteins (bait) with the directly bound ones (fish), forming immuncomplexes
that are pulled down by the effect of the antibody attached beads. The non-attached
proteins are washed away leaving the protein of interest in the tube for further
analysis (Phizicky & Fields, 1995)
In the current study Anti-c-Myc Agarose slurry (Thermo Scientific, USA)
was used to pull down c-Myc tagged proteins from whole cell lysates (WCL), by
adding 50 µl of slurry to 150 µl of WCL after washing the slurry with sufficient
volumes of TBST/Halt Protease & Phosphatase Inhibitor Cocktail (100x) (Thermo
Scientific, USA) 3 times, centrifuging at 3000 x g for 2-3 minutes and decanting. The
mixture was incubated in a rotator at 4 ºC for 2-3 hours to allow binding. Next, the
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immuncomplex was washed again with TBST/Protease Phosphatase Inhibitor
Cocktail three times to remove unbound protein. There are different elusion
protocols that can be followed to elute the proteins out of the beaded antibodies, the
one used in this experiment was the chemical elusion using the non-reducing buffer
(product # 1859594, Thermo Scientific, USA). 2X of the elusion buffer was added to
the proteins, boiled at 98 ºC for 5 minutes, chilled, centrifuged at 3000 x g for 2-3
minutes and supernatant containing the proteins, only, collected and loaded in the
wells.
2.3.7 Oligonucleotide Primer Design
DNA or complementary DNA (cDNA) primers were designed using Primer3
software (www.primer3.ut.ee) (Untergasser et al., 2012) to amplify by PCR the
genomic regions harboring the identified variants. The designed primers were
ordered from Metabion Inc, Germany (http://www.metabion.com/).
On the other hand, site-directed mutagenesis (SDM) primers were designed
using PrimerX (www.bioinformatics.org/primerx/) and the primers and probes used
for the real time PCR experiments were ordered from TaqMan Real-Time PCR
Assays (Thermo Fisher Scientific, Waltham, MA).
2.3.8 General PCR Protocol
Upon receipt of primers, the desired DNA or cDNA fragments to be
sequenced were amplified using Taqman polymerase kit (Qiagen. Gmbh, Germany).
In general, 0.5 µl of DNA is added to 2 µl of 10x buffer and 4 µl of Q buffer/5%
Dimethyl Sulfoxide (DMSO) (New England BioLabs, USA) or Betaine (Sigma,
USA). Additionally, 0.2 µl of deoxynucleotriphosphate (dNTPs) (Promega, USA),
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0.1 µl of Taq polymerase, and 0.6 µl of each of forward and reverse primers were
added and the reaction mixtures topped to 20 µl total volume by nuclease free water.
In the case of cDNA amplification, the template was added to 5x GoTaq® Flexi
buffer (Promega, USA) to 25 µM MgCl2, 0.25 µl GoTaq® Flexi DNA polymerase
(Promega, USA), dNTPs and primers to a total volume of 25 µl.
The reaction tubes were transferred to the Veriti thermal cycler (Applied
Biosystems, USA) and 35 amplification cycles were run as follows; an initial
denaturation at 95 ºC for 5 minutes, followed by 94 ºC for 30 seconds and annealing
for 30 to 45 seconds at variable temperatures depending on the melting temperatures
of the PCR primers, then the elongation step at 72 ºC for 45 seconds followed by
final extension at 72 ºC for 7 minutes, finally, tubes were kept at 4 ºC until analysis
or appropriate storage.
2.3.9 PCR Products Purification
This protocol was performed to purify double-stranded DNA fragments from
PCR reactions when required. PCR DNAs are purified from unused primers,
nucleotides, polymerases and salts. The procedure in this study was strictly followed
according to the manufacturers of the MinElute PCR Purification Kit (Qiagen, USA).
To each volume of PCR, 5 volumes of buffer PB were added and the mixture
assembled on the vacuum manifold and vacuum applied. The membranes were then
washed by adding 750 µl of buffer PE. To remove the residual ethanol from PE
buffer, the columns were transferred into 1.5 ml microcentrifuge tubes and spun at
10,000 x g for 1 minute. The last step was eluting DNA by adding 10 µl of buffer EB
to the center of the membrane, let stand for 1 minute then centrifuged to collect
DNA.
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2.3.10 Reverse Transcription of mRNAs
Reverse transcription refers to the conversion of mRNA into cDNA using
reverse transcriptase (RT) enzymes, which were initially discovered in retroviruses
owing the capability of reverting their RNAs back into DNA to integrate into the
host’s genomic DNA.
Random primers were added to previously normalized RNA samples and the
mixtures were heated at 70 ºC for 4 minutes to denature the RNA secondary
structures, then chilled on ice for 5 minutes. Next, a master mix of 0.5 µl GoScript
reverse transcriptase enzyme 1 µl RNasin Ribonuclease Inhibitor, 4 µl GoScript
buffer and 4 µl MgCl2 (Promega, USA), were added to the previous mixture and run
in the PCR machine. The reaction starts at 25 ºC to anneal the primers to the RNA
for 5 minutes, heated up at 42 ºC for 60 minutes to synthesize the new strands. The
reaction is terminated by increasing the temperature to 70 ºC for 15 minutes to
inactivate RT enzyme.
2.3.11 Real-Time Quantitative PCR
In this study, comparative quantitation of mRNAs after conversion to cDNAs
was performed in some cases to study the gene expression of the target genes. Data
was generated as fold change among the patient and the normal control using
hypoxanthine phosphoribosyltransferase gene (HPRT) or Glyceraldehyde 3phosphate dehydrogenase (GAPDH) as endogenous controls since they are both
house-keeping genes that are constantly expressed in cells.
TaqMan PCR universal buffer (Applied Biosystems, Carlsbad, CA) contains
all the necessary components except for the gene specific primers and probes. The
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exact components and their concentrations can be found in the TaqMan assay
brochure.
TaqMan probe is an oligonucleotide that contains a reporter dye at the 5’ end
and a florescent quencher at the 3’ end. Once the primer binds to the template and the
strand synthesis begins, the nuclease activity of the Taq polymerase will cleave the
probe releasing the quencher dye from the reporter dye, hence, giving a signal of
amplification. This reaction is repeated in 40 cycles, and if a signal exceeded the
threshold it will then be considered as a real signal, referred to as threshold cycle
(Ct), this occurs in the exponential phase until no more cDNA is amplified (plateau
phase).
In Real-Time PCR, the patient’s RNA as well as the control should be
normalized prior to starting the RT-PCR reactions. Normalization is performed first
by measuring its amount using nanodrop spectrometer, and by pipetting equal
concentrations of all RNA samples, then performing reverse transcriptase explained
in section (2.3.10). Then 2µl of cDNA were added to 10 µl of TaqMan universal
master mix and 1 µl of TaqMan assay and topped up to 20 µl with nuclease-free
water. At least, a triplicate of each sample should be used to calculate the mean Ct
values as well as the standard deviation to measure the ∆∆ Ct values. The plate is
then transferred to QuantStudioTM Real-Time PCR machine (Applied Biosystems,
Carlsbad, CA), and the software did the data analysis and measurements including
quality control (QC) analysis.
2.3.12 Agarose Gel Electrophoresis
Once the targeted regions of the genome have been amplified by PCR, they
could be visualized as separate DNA fragments on agarose gels according to their
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molecular sizes. This method involves running a current through a prepared agarose
gel using an electrophoresis device. The agarose gel itself is prepared by mixing the
required agarose powder with water and ethidium bromide (EtBr) to reach a final
concentration of 0.5 µg/ml. To estimate the size of the PCR product, the separated
bands are compared to a standard ladder of DNA fragments of variable sizes, and
viewed in Bio-Rad gel imaging system (Bio-Rad, USA).
2.3.13 Sodium Dodecyl Sulfate Poly Acrylamide Gel Electrophoresis (SDSPAGE) and Western Blotting (WB)
SDS-PAGE is the most commonly used method to separate and analyze
proteins (Saraswathy & Ramalingam, 2011). After proteins were extracted and their
concentrations determined, an aliquot was added to Laemmli buffer containing 1.8 µl
β-mercaptoethanol as a reducing agent, 2 ml glycerol, 0.5 M Tris-HCL, pH 6.8 and 6
ml 20% SDS, the mixture was boiled at 98 ºC for 5 minutes to destroy the secondary
and tertiary structures of the protein and give a uniformly negative charge. The name
of the technique comes from the constituents of the gel, having 40% acrylamide/bis
solution (Bio-Rad, USA), 1.5/0.5 M Tris-HCL, 10% SDS, 10% ammonium
persulfate (APS), and ultra-pure N,N,N′,N′-Tetramethylethylenediamine (TEMED)
(Invitrogen- Thermo Fisher Scientific, USA).
Equal amounts of proteins were loaded into the wells of the SDS-PAGE gels
along with the Biorad Precision Plus Protein Dual Xtra Standard (Bio-Rad, USA)
and run in the in-house prepared 1x running buffer. To carry out Western blotting
analysis, gels were then transferred onto a nitrocellulose membrane (GEHealth Life
Sciences, USA) using the semi-dry transferring technique in Bio-Rad semi-dry
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blotter. Later, membranes were washed and blocked in either 3% BSA (Sigma, USA)
or 5% non-fat milk, depending on the type of antibody used.
After blocking, the blots were incubated with primary antibodies over night at
4 ºC, followed by washing steps with 1x Tris-buffered saline, 0.1% Tween 20
(TBST) for 3 times then probed with the secondary antibodies for 1 hour at room
temperature. Finally, the blot was developed using Pierce ECL western blot substrate
(Thermo Fisher Scientific, Waltham, MA). Images were captured by Typhoon
FLA9500Imager (GEHealthcare Life Sciences, Logan, UT).
The loading controls used in all experiments were monoclonal mouse antitubulin antibodies (dilution: 1:15,000; Santa Cruz Biotechnology Inc., USA), and
polyclonal rabbit anti-GAPDH antibody (dilution: 1:2500: Abcam, UK).
In order to investigate more than one protein on the same membrane and use
different primary and secondary antibodies, one can strip the membranes using either
gentle or harsh stripping protocols. In this study the harsh stripping protocol was
performed on blots by incubating the membranes in a 55 ºC water bath after adding
the following in-house reagents; 20 ml of 10% SDS, 6.5 ml Tris-HCL pH (6.8), 0.7
ml β-mercaptoethanol (Sigma, USA), and topped up to 100 ml with water. The
mixture was incubated with the membrane for 15 minutes, discarded and re-topped
with fresh mixture again. Later, the membranes were washed with running tap water
for 15 minutes, then with distilled water for 5 minutes, followed by three times wash
with 1X PBS. To reprobe the membranes with other antibodies, they were first
blocked with 5% skimmed milk or 3% BSA/TBST for 1 hour.
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2.3.14 Direct Sanger Sequencing of PCR Products and cDNAs
Amplified DNA or cDNA fragments were sequenced with the relevant
primers using the Sanger chain termination method on the 3130xl Genetic Analyzer
(Applied Biosystems, USA).
The PCR products were cleaned up with Exonuclease 1/Shrimp Alkaline
Phosphatase (Exo/SAP-IT) enzymes (Applied Biosystems, USA) to remove the
unused oligos and dNTPs. This step was followed by the cycle-sequencing reaction
where we added 1 µl of Big Dye Terminator to the mixture and kept on ice for 30
minutes. Then 5x buffer, water and primers were added and run on the PCR machine.
Afterwards, purification step was performed by adding 125 mM EDTA and 95%
ethanol to precipitate the resulting DNA fragments. The reactions were then
incubated at -20 ºC for 30 minutes, spun, decanted, and washed by 70% ethanol.
Sanger sequencer sequences one strand, thus, to denature the other, 15 µl formamide
was added and heated at 96 ºC.
The results were generated as chromatograms and nucleotide sequence
documents were further aligned and analyzed using BioEdit software and Clustal
Omega algorithms (www.ebi.ac.uk/Tools/msa/clustalo/) (Sievers et al., 2011).
2.3.15 Plasmid Sanger Direct Sequencing
The used human cDNA clones were purchased from Genecopoeia
(GeneCopoeia, Rockville) (www.genecopoeia.com) and OriGene (OriGene, USA)
(www.Origene.com). The plasmids were supplied lyophilized as well as their
sequencing primers. Once reconstituted, the plasmids were transformed into
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competent E. coli cells for amplification and then extracted with plasmid Miniprep
kit (Qiagen, USA).
Extracted plasmids were directly sequenced after cutting with the appropriate
restriction enzyme, then 4 µl of the plasmid DNA was added to 2 µl of either
primers, 2 µl of Big Dye Terminator and 5x buffer. The mixture was then run on the
PCR machine at 90 ºC for 5 minutes as initial denaturation step, followed by 30
seconds, then at 60 ºC for 4 minutes, the cycle is repeated 35 times. The final step
before loading the sequencer should be the purification step as mentioned earlier.
2.3.16 Whole Exome Sequencing
Whole Exome sequencing for families 3 and 4 was performed at Sengenics,
Kuala Lumpur, Malaysia (www.sengenics.com) on the affected children of families 3
and 4 using the Illumina HiSeq 2500 platform, sequencing the coding regions of the
DNA (exons) which comprise 1-2% of the whole genome and which is expected to
harbor more than 90% of the disease-causing mutations.
With a powerful, high-throughput system, HiSeq 2500 can sequence 5-75
exomes per run. Starting with library pooling and exome enrichment with 2.5 days
turn-around time, followed by (sequencing by synthesis method) which lasts for 5
days, and ultimately analyzing alignment, detecting structural aberrations

and

CNVs, as well as variants annotation using software calculation systems which takes
from 2-3 hours (www.illumina.com).
10 µg of high quality total genomic DNA of each sample was submitted with
a total concentration of 50-200 ng/µl. The quality of the submitted DNA samples was
determined using the appropriate Nanodrop measurements.
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Whole Exome sequencing on families 1 and 2 was conducted as a service at
Baylor College Genetics Laboratory (www.bcmgeneticlabs.org) on the affected
children and the following quality control metrics of sequencing data were generally
achieved: >70% of reads aligned to target, >95% target base covered at >20x, >85%
target base covered at >40x, mean coverage of target bases >100x. As a quality
control measure, the individual’s DNA was also analyzed by SNP-array, and
compared with the WES data, SNP concordance to genotype array: >99%. The test
might not provide detection of certain genes due to local sequence characteristics or
presence of closely related pseudogenes. Gross deletions or duplications might have
not been accurately identified by this methodology.
2.3.17 Whole-Genome SNP Genotyping and Homozygosity Mapping
SNP genotyping was performed as a service by ATLAS Biolabs, GmbH ,
Germany (www.atlas-biolabs.com) using Genome Wide Affymetrix SNP 6.0
genotyping assay, which can detect around 900 K SNPs and 900 K CNV markers.
DNA samples of all available family members (affected and non-affected
members) were submitted with high quality DNA, the data was generated as wildtype SNP allele (A) and the alternative allele (B). Affymetrix 6.0 utilizes intensity
QC metrics and signature SNP genotype calls to assure the quality control. The QC
analysis provides an estimate of the overall quality for a sample based on the contrast
QC algorithm as the primary method, in addition to the dynamic model algorithm.
Contrast QC criteria have a Birdseed genotyping call rate of at least 97% and an
accuracy of at least 99% (with average performance significantly higher) when
analyzed with Genotyping Console at default settings. Contrast QC is the
recommended QC metric for the Genome-Wide Human SNP 6.0 array. The default
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threshold is >=0.4 for each sample. Gender analysis was also performed during the
QC step. It provides a gender call that will be used to select models for the X and Y
chromosomes during genotyping. The Genome-Wide Human SNP Array 6.0
contains SNPs and CN probe sets from two enzyme sets (Nsp and Sty). Some SNPs
and CN probe sets are only present on fragments generated by one of the enzymes,
while other SNPs and CN probe sets are present on fragments generated from both of
the enzymes. There are situations where a sample may work properly with one
enzyme set, but not with the other. Different processes are used for the gender call,
depending upon the type of array being analyzed. Genotyping Console supports
genotyping analysis for Birdseed v1 or Birdseed v2 algorithms.
Subsequently, data was uploaded in the homozygosity mapper software
(www.homozygositymapper.org). The Genome Wide SNP 6.0 chip was selected, and
the analyzed patients’ IDs were checked as cases, while the healthy were checked as
controls. Selecting the default settings was accurately sufficient to get the runs of
homozygosities across the genomes, they included checking genetic homogeneity
option to detect regions in which all the affected individuals were homozygous.
Regions with the disease haplotype were excluded if they were longer than 4000. In
order to count all the homozygous blocks, the lower limit of length was selected as
zero. The resulting graphical interfaces were obtained from GeneDistiller where all
candidate genes in long homozygous regions were queried. To emphasize interesting
regions, scores higher than 80% of the maximum score were shown in red, whereas
smaller decreases of the score within a homozygous region were neglected (black
bars). GeneDistiller provided generous information on the proteins and their
interactors, phenotypes, expression, cellular localization and more.
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(http://www.homozygositymapper.org/HomozygosityMapper/tutorial#analysis)
(Alkuraya, 2010).
2.3.18 NGS Variants Filtration and Pathogenicity Prediction
The sequenced reads were aligned to human genome version 19 (hg19). 92%
of the sequenced bases have a quality score more than 30 (Q30), Q score refers to the
probability of a correct call, with greater sequencing depth.
After excluding CNVs and other structural variants by CGH array, runs of
homozygosity (ROH) were applied on the WES data by detecting stretches of
homozygous genotypes using DNA markers at consecutive positions spanning one
marker every 3 kb or less. The graphical interface of the results presented by bar
graphs could be zoomed to view the chromosomes harbored. Such that the red bars
(exceeded the threshold) were included, whereas the black ones were not.
Furthermore, segments of sizes more than 2 cM were included in the study (Woods
et al., 2006). The downstream variants’ filtration and prioritization has been
conducted by Al-Jezawi N. K, by establishing an integrated WES data filtering
approach aiming first to extract essential variants calls such as missense, stop gained,
frameshifts and splice-site variants, thus excluding deep intronic, synonymous, and
variants located at the 3 prime UTRs, compared to the exome variant server
(www.evs.gs.washington.edu),

the

1000

Genome

project

(www.browser.1000genomes.org), GalaxC (www.galaxc.sengenics.com), ExAC
database

(www.exac.broadinstitute.org)

and

GME

variome

project

(http://igm.ucsd.edu/gme/). Variants with minor allelic frequency (MAF) more than
0.01 were excluded as well.
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The predicted effects of the identified variants on the protein function were
identified using SFIT, PolyPhen, Provean, Mutation Taster and FATHMM. The nondamaging, tolerated or benign variants were excluded. More Bioinformatics analyses
were performed, and are demonstrated in later sections.
A very important criterion in filtering was to find out damaging variants, if
any, that existed in a homozygous state of the candidate genes in normal individuals,
inferring a dispensable role of the resulting protein. At a final stage, all the candidate
genes were cross-matched in the affected siblings as well as performing segregation
analyses by genotyping using Sanger sequencing on all the family members.
2.3.19 Comparative Genomic Hybridization
CGH array was performed as a service at Sengenics (www.sengenics.com) on
patients’ DNA samples using Chip microarray, using test and control genomes which
were differently labelled and hybridized to a microarray chip. This florescent chip
was later scanned and measured by a software. CGH is used to study CNVs and
other structural aberrations in the human genome.
2.3.20 Cell Culture and Transient Transfection
The primary cell lines used in this study were normal control or patients’
fibroblasts derived from skin biopsies. Commonly available cell lines were also used
for some experiments including HEK293T, HeLa and SH-SY5Y cells. Cells were
maintained in DMEM supplemented with 10% fetal bovine serum, 4mM LGlutamine,

4,500

mg/L

Glucose,

Sodium

Pyruvate,

and

100

U/ml

Penicillin/Streptomycin. For SH-SY5Y cells, they were maintained in DMEM/F12
(Thermo Fischer Scientific, USA) and 15% of fetal bovine serum was added. Cells
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were passaged every 3 days upon reaching 70-80% confluency. HeLa and SH-SY5Y
cells used for immunofluorescence assay were seeded on 24-well plate sterilized
coverslips, incubated for 24 hours, followed by transfection with the wild and the
generated mutants. On the other hand, HEK293T and fibroblast cells which were
used for protein extraction and western blot analysis, were seeded with a density of
2.5 × 105 cells/well in 6-well plates for 48 hours. HEK293T cells were transfected
with the needed plasmid using the Promega, Madison, WI, FuGENE HD transfection
kit (Promega, USA), with a DNA/FuGENE ratio of 1:3, respectively.
2.3.21 Site Directed Mutagenesis
Mutations generated in the cDNA plasmid constructs were performed with
Pfu Ultra High-Fidelity DNA polymerase (Stratagene, USA). 20 ng of the template
plasmid was added to 0.5 µl of each of the designed primers, 0.5 of the dNTPs
mixture, 2.5 µl of the 10x Pfu Ultra Buffer, 5 µl Q-solution and 0.5 µl of the Pfu
enzyme. The reaction was later run on the PCR thermocycler on the following
program; initial denaturation at 95 ºC for 5 minutes, denaturation at 94 ºC for 30
seconds, followed by annealing for 1:30 minutes, and ending with the elongation step
at 70 ºC for 18 minutes and post-elongation at 72 ºC for 20 minutes, repeating them
20 times.
Subsequently, mutagenesis PCR products are cleaned up from the remaining
templates using DpnI enzyme (0.3) µl with the PCR product (10 µl) for 3-4 hours.
These products were used to transform E. coli ultra-competent cells and colonies
were picked and their plasmids were tested, by direct DNA sequencing, for the
introduction of the desired mutation.
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2.3.22 Plasmid Transformation and Purification
Plasmids, either wild types or mutants were transformed into E. coli
competent cells on ice during log phase for 30 minutes, then heat shocked at 42 ºC
for 45 seconds. After the cells were chilled again, 500 µl of Laurel broth (LB) was
added with 2 µl of 1 M glucose (Sigma, USA) per ml and incubated shaking at 37 ºC
for 30-45 minutes. Afterwards, tubes were centrifuged at 4000 RPM for 5 minutes to
collect the sediment then they were streaked onto LB-agar plates for no longer than
16 hours.
On the next day, single colonies were inoculated in LB broth supplemented
with 1 µl of the relevant antibiotic per 1 ml of the broth, and kept shaking at 37 ºC
for 16 hours.
On the following day, plasmid extraction was performed following the
manufacturer’s instructions for Miniprep kit (Qiagen, USA). The bacterial cells were
collected after centrifuging the tubes at 4000 RPM, 4 ºC for 6 minutes. Supernatants
were discarded and 250 µl of P1 buffer was added to each tube to lyse the bacterial
cells, mixed and transferred into a 1.5 µl centrifuge tube. Then 250 µl of P2 buffer
was added, followed by 350 µl of N3 buffer to neutralize the lysate, clumps were
formed, then the lysate was separated by centrifugation at 12,000 RPM for 10
minutes. To remove the endonucleases, 0.5 ml PB buffer was added while the tubes
were assembled in the column tube supported on a vacuum pump. Subsequently,
salts were removed efficiently by adding 0.75 ml of PE buffer. Finally, plasmids
were eluted with either water or EB buffer making sure the pH was within 7.0-8.5.
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2.3.23 Confocal Microscopy
Transfected HeLa or SH-SY5Y cells grown on coverslips were washed three
times with PBS, fixed with methanol for 5 min at −20 °C, and blocked by 2% BSA
for 1 hour. Specific primary antibody dilutions were added to the cover slips as the
primary antibody, part of them were incubated with ER marker anti- calnexin goat
(C20) polyclonal antibody (dilution: 1:50; Santa Cruz Biotechnology Inc., Dallas,
Texas) whereas, the rest were incubated with the Golgi marker anti- Golgin-97
mouse monoclonal antibody (dilution: 1:100; Cell Signaling Technology,Danvers,
MA). For Myc-tagged proteins, mouse-anti-Myc-tag monoclonal antibody (dilution:
1:200; Cell Signaling Technology) were added. Whereas in case of using antibodies
against the XYLT1 protein, Polyclonal rabbit anti-XYLT1 antibodies were used
(dilution: 1:50; Sigma, USA), all were incubated for 1 hour at room temperature in
dark. In other experiments where plasma membrane localization was studied, GFPH-Ras plasmids were used by mixing 0.3 µg of plasmids with Gibco™ Opti-MEM™
I Reduced Serum Media (Opti-MEM) followed by 3:1 ratio of FuGENE:DNA,
respectively. Moreover, another plasmsa membrane marker was used that is
ubiquitously expressed in cells, that was rabbit polyclonal sodium/potassium-ATPase
(Na+/K+-ATPaseα (H-300): sc-28800) (Santa Cruz Biotechnology Inc, USA). Cells
were then washed three times with PBS and incubated with the following respective
secondary antibodies for 45 minutes at room temperature in dark: Anti-rabbit IgG
(H+ L) F(ab)2 Fragment (Alexa Flour 488 conjugate) (dilution: 1:1000; Cell
Signaling Technology, Danvers, MA) to respective wells, anti-mouse IgG (H + L)
F(ab)2 Fragment (Alexa Flour 555 conjugate) (dilution: 1:1000; Cell Signaling
Technology) to respective wells, and anti-goat IgG (Alexa Flour 555 conjugate)
(dilution:1:1000;

Life

Technologies,

Carlsbad,

CA)

to

respective

wells.
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Subsequently, cells were washed and mounted with immunofluor medium (ICN
Biomedicals). Between 100 and 200 transfected cells for each construct were
inspected and at least images of 10 cells were acquired using Nikon confocal Eclipse
80I microscope (Japan). Some experiments were performed in duplicates, others in
triplicates and in some cases even more.
2.3.24 Cloning and Construction of the Mini-Gene Vector
To assess splice-site variants when patients’ cells were not available or
inaccessible, hybrid mini-genes have been developed to determine the impairment of
suspected variants on the splicing machinery (Deguillien et al., 2001).
In the current study, the splicing cassette (p(13,17)/CMV) was designed by
Deguillies and colleagues using pRc/CMV, 5.5 kb plasmid, where exons 13 and 17
with their downstream and upstream flanking intron of the erythrocyte membrane
protein band 4.1 gene (4.1R/EPB41) were cloned (Deguillien et al., 2001). One of
our variants (c.394G>A) of Multiple PDZ domain gene (MPDZ), was located on the
first nucleotide of exon 5, and this variant was a component of a compound
heterozygous mutations leading to a hydrocephalus case of one patient. One possible
implication of this variant was to cause a splice-site effect on the mRNA level, and
therefore to examine that, exon 5 and parts of its flanking introns were sub-cloned
into the mini-cassette vector which harbors exons 13 and 17 and their flanking
introns of (EPB41). The intron between exons 13 and 17 has multiple cloning sites
including restriction sites for BSTEII (GGTCACC) and NheI (GCTAGC) enzymes
(New England Biolabs, USA). Thus, cloning primers were designed containing those
REs. Forward primer: 5’-ATGTGGGTCACCACACTTACTAAG-3’, Reverse
primer: 5’- TATTATGGGTCATTGCTAGCATGG-3’. Making sure the REs sites
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were not within the desired fragment, after amplifying the genomic fragment of
MPDZ gene from a normal control genome which was around 647 bps, and which
was performed by adding 1 µl of Pfu Ultra High-Fidelity DNA polymerase
(Stratagene, USA), to 1 µl of dNTPs, 1.6 µl of each of the forward and reverse
primers, 5 µl of 10x Pfu Ultra Buffer, and 1 µl of DNA, then topped with water to a
total volume of 50 µl, the reaction was run on the thermo-cycler using the following
PCR program; initial denaturation at 95 ºC for 5 minutes, followed by denaturation at
94 ºC for 30 seconds, then the annealing step was adjusted according to the Tm of
the primers for 1:30 minutes, further step was the elongation at 72 ºC for 1:30
minutes (2 min/Kb), and a final elongation for 7 minutes. The product was further
purified using MinElute PCR Purification Kit (Qiagen. Gmbh, Germany).
Meanwhile, the respective enzymes were checked from Double Digest Finder
(www.neb.com) and found to be non-compatible, so a sequential digestion was
required, starting with the enzyme of lower temperature (NheI) with an optimal
temperature of 37 ºC. Separate reactions were attempted for the vectors and the
insert, such that 1 µg of the vector and separately, all the amount of the insert were
added to 1 µl of NheI with 5 µl of BSA and 5 µl of 2.1 buffer (New England Biolabs,
USA), then topped up with water to 50 µl reaction and incubated at 37 ºC for 2
hours. The enzymatic reaction was stopped by deactivating the reactions at 65 ºC for
15 minutes. Directly after, the digested vector was checked on gel electrophoresis to
view the linearized cut vector appearing ‘heavier’ compared to the non-digested. The
next step was applying the second enzyme (BSTEII) by adding 1 µl of the enzyme
and 5 µl of 3.1 buffer to the previous reaction and incubated for 2 hours at 60 ºC,
then deactivated similarly. To detect that the vector was cut, it was run on gel along
with the non-digested and the first digestion, to observe a lower band at the expected
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molecular weight. Subsequently, gel purified using MinElute Gel Extraction Kit
(Qiagen. Gmbh, Germany).
The PCR product of MPDZ gene was then ligated to the vector using 1 µl of
T4 DNA ligase, and a molar ratio of vector/insert ranging from 1:3-1:15, calculated
using in silico ligation calculator (www.insilico.uni-duesseldorf.de). To the previous
mixture, 2 µl of T4 DNA ligase buffer was added and topped with water to 20 µl.
The reaction was optimized at two different conditions; at RT for 30 minutes or at
16 ºC overnight. Eventually, all the attempted plasmid clones were transformed,
extracted, then verified by sequencing using the sequencing primers T7 and Sp6
(Figure 8).
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Figure 8: An illustration for the preparation of the recombinant plasmid for minigene construct. A) A schematic model of the mini-cassette plasmid with the cloned
13 & 17 exons of EPB41 gene. B) The digestion steps using NheI then BSTEII on
the vector, a linearized plasmid observed after the nicking appearing at a higher
molecular weight. C) The ligation of the vector with exon 5 and its flanking introns
of MPDZ gene showing higher molecular weight (6.6 kb) owing to the insertion of
647 bp.
To generate the mutant construct, site-directed mutagenesis (SDM) was
performed on the vector harboring the wild-type MPDZ using the following primers:
Forward primer: 5’-TCCTAAACAGAGTCGCCATG- 3’, Reverse primer:

5’-

CATGGCGACTCTGTTTAGGA-3’, the mutant vector was as well sequenced to
confirm mutagenesis.
HEK 293T cells were maintained in DMEM, supplemented with 10% fetal
bovine serum, 4 mM L-Glutamine, 4500 mg/L Glucose, Sodium Pyruvate, and 100
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U/ml Penicillin/Streptomycin. Then they were seeded in 6-well plate. On the
following day, wells were transfected with the wild-type minigene construct, while
the others were transfected with the mutant and cultured for 24 hours at 37 °C, 5%
CO2. The following day, cells were scraped and washed with PBS and RNA was
extracted using SV Total RNA Isolation system (Promega, USA), then reverse
transcribed with random primers and GoScript reverse transcriptase enzyme
according to the manufacturer’s instructions (Promega, USA). Subsequently, the
resulting cDNA was analyzed on agarose gel electrophoresis and sequenced with the
following primers; F: 5’ GTGGTCCCTAAGGCACAGAA 3’ and R: 5’
CCGTGGTTCGGGTACCG 3’ to assess RNA splicing.
2.3.25 Glycosidases Sensitivity and Resistance Assays
There are many enzymes that are used to study the structure and function of
glycoproteins, among which are the endoglycosidase H (Endo H), Endo D, Endo F2,
Peptide N-glycosidase F (PNGase F), etc. Each of them cleaves at specific site of the
glycans. For example, Endo H cleaves between two N-Acetylglucosamines
(GlcNAc) leaving one residue attached to the asparagine (Asn) residue of the protein.
This assay is used experimentally to determine if glycoproteins contain highmannose or hybrid oligosaccharides to distinguish ER and post-ER passage. So any
glycoproteins that progress to later Golgi (medial and trans-Golgi apparatus) stages
become more resistant and therefore the glycan moiety becomes resistant to cleavage
by Endo H. Whereas PNGase F enzyme can cleave all the carbohydrate chains
leaving only asparagine converted to aspartate, thus, even complex glycans are
sensitive to it. The cleavage sites of the various glycosidases are illustrated in
Figure 9.
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Figure 9: Illustration of the glycosidase enzymes. A) Endo H cleaves between two
GlcNAcs leaving one attached to the asparagine. Whereas, PNGase F cleaves
between the GlcNAc and asparagine releasing all the glycan chain from the core
protein (www.sigmaldrich.com). B) A comparison between the different glycosidase
enzymes on the high mannose versus complex and hybrid forms of glycoproteins
(Freeze & Kranz, 2010).
Endo H assay (Product Number A0810Sigma, USA) can be performed either
on whole cell lysates or immunoprecipitates, in which case about 20 µg of protein
was added to 2µl of denaturation buffer and were incubated at 98 ºC for 5 minutes to
destroy the secondary and tertiary structures of the proteins. After chilling on ice, 8
µl of sodium phosphate buffer was added to reach an optimum pH of 5.0-6.0. The
sample was then divided into two tubes; one was left undigested, whereas 2 µl of
Endo H enzyme were added to the other, both reactions were incubated at 37 ºC for 4
hours. This assay is used to distinguish pre-Golgi forms (sensitive) from the postgolgi forms (resistant).

61
On the other hand, the most universal amidase is PNGase F, cleaving most
complex structures except for α 1,3 fucose and the presence of one GlcNAc attached
to asparagine. However, in some cases, the high molecular weight of this enzyme (37
kDa) could limit its accessibility to the protein cleavage site (Thobhani, Yuen,
Bailey, & Jones, 2009).
To 1-20 µg of proteins, 1 µl of denaturing buffer (10x) was added and topped
up to 10 µl with water and denatured at 100 ºC for 10 minutes. After chilling, 2 µl of
GlycoBuffer 2 (10x), 2 µl 10% NP-40 and 6 µl of water were added. NP-40 was used
to protect the enzymatic activity from the denaturation step. Next, 1 µl of PNGase F
was added to the previous mixture and incubated at 37 ºC for 24 hours (New England
Biolabs, USA). Digested proteins were subsequently checked by western blotting.
2.3.26 Protein Structural Modeling
One of the approaches to add more evidence to the pathogenesis of variants in
genetic diseases is protein structural modeling. Protein modeling may allow the
detection of both structural and functional changes of the protein of interest with
genetic variation. This type of investigation was used as a class of evidence
explaining the implication of variants in genetic diseases.
In this study, protein models were conducted by Dr. Ranjit Vijayan from the
Department of Biology, College of Science, United Arab Emirates University using
PyMOL (www.pymol.org) and Schrodinger Prime (www.schrodinger.com).
The protein structure of one of the affected domains in MPDZ protein was
constructed by matching its sequence to an evolutionarily related protein (homology
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modeling), due to the unavailability of a human structure. In our case it was the rat
PDZ4 structure (PDB ID: 4XH7).
2.3.27 Bioinformatics and Computational Analysis
Bioinformatics is a science of employing the power of computing to analyze
biological data. Numerous bioinformatics softwares and programs have been
developed over years to help with biodata analysis. Table 1 summarizes some of the
resources and bioinformatics tools utilized in this study.

Table 1: Classes of the main bioinformatics tools and databases used in this study
Bioinformatics
Tool/Resource

Analysis Description

Ensembl Genome
Browser

Genes annotations, alignments, predictions, disease data, www.ensembl.org
sequence variations

OMIM

Human genes and genetic phenotypes, information about www.omim.org
Mendelian disorders

NCBI

Gene organization, sequence analysis, structure prediction, www.ncbi.nlm.nih.gov
mathematical modeling, sequence alignment, gene expression

University of
California Santa Cruz
(UCSC) Genome
Browser

Visualizing genomic data, blast analysis, variant annotations, In www.genome.ucsc.edu
silico PCR and more

Uniprot

Peptide search, blast, Alignment, protein sequence and www.uniprot.org
functional information

STRING

Information
interactions

HGMD

A database of all published genes and mutations responsible for www.hgmd.cf.ac.uk
inherited disorders

on

known

Website

and

predicted

protein-protein www.string-db.org
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Table 1: Classes of the main bioinformatics tools and databases used in this study (Continued)
Bioinformatics
Tool/Resource

Analysis Description

Website

ExAC Browser

WES data of individuals excluding severe pediatric cases, www.exac.broadinstitute.org
useful reference for allelic frequencies

Exome Variant Server

WES data and SNPs, variants information summarized www.evs.gs.washington.edu
according to different population, protein prediction

1000 Genome Browser

A source of human genetic variation with frequencies more www.browser.1000genomes.org
than 1%

GalaxC

Allele frequency database of Arab disease mutations

Clustal Omega

Pairwise and multiple sequence alignment with either DNA or www.ebi.ac.uk/Tools/msa/clustalo/
protein entry format

BLAST

Compares nucleotide or protein sequences to databases and www.blast.ncbi.nlm.nih.gov/Blast.c
measuring the statistical significance
gi

Protein Atlas

Demonstrates gene expression of transcriptomes and proteomes www.proteinatlas.org
in human tissues and cells

www.galaxc.sengenics.com
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Table 1: Classes of the main bioinformatics tools and databases used in this study (Continued)
Bioinformatics
Tool/Resource

Analysis Description

Website

Gene Cards

Searchable database for all annotated human genes providing www.genecards.org
information on genes, transcriptomes, proteins and clinical
information

SIFT and Provean

Predict the effect of amino acid substitution by entering the www.provean.jcvi.org
chromosome number, genomic location and the nucleotide
susbstitution

PolyPhen v2

Predicts possible impact of an amino acid substitution on the www.genetics.bwh.harvard.edu/pph
structure and function of a human protein by entering the 2/
protein identifier and the amino acid substitution

Mutation Taster

Predicts the effect of substitutions, deletions or insertions, www.mutationtaster.org
summarizes the allelic frequencies from different databases,
scores the conservation among multiple species

FATHMM

Predicts the functional effects of missense variants on proteins

www.omictools.com/fathmm-mkltool

Automated Splice Site
and Exon Definition
Analyses (ASSEDA)

Predicts the effect of splice-site variants on mRNA

www.splice.uwo.ca
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Table 1: Classes of the main bioinformatics tools and databases used in this study (Continued)
Bioinformatics
Tool/Resource

Analysis Description

Website

Human Splice-Site
Finder v2.4.1

Predicts the effect of splice-site variants on mRNA and www.umd.be/HSF
calculating the consensus values of potential splice-sites

Neural Network

Predicts the effect of splice-site variants on mRNA and giving www.fruitfly.org/seq_tools/splice.ht
scores of the cryptic splice-sites.
ml

Primer3 v 0.4.0

To design PCR primers

www.primer3.ut.ee

PrimerX

To design mutagenic PCR primers

www.bioinformatics.org/primerx/

Homozygosity Mapper

Generating a report and a graph for the homozygous regions of www.homozygositymapper.org/
the entered SNPs genotype data using GeneDistiller software

The Jackson
Laboratory (JAX)

Provides information about animal models with regard to https://www.jax.org
mutations and many other useful applications

cNLS Mapper

Prediction of importin α-dependent nuclear localization signals

Gene Matcher

Enables connections between clinicians and researchers around www.genemathcer.org
the world to share their genes and variants.

http://nls-mapper.iab.keio.ac.jp/cgibin/NLS_Mapper_form.cgi
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Chapter 3: Results

3.1 Compound Heterozygous Variants in the Multiple PDZ Domain Protein
(MPDZ) Cause a Case of Mild Non-Progressive Communicating
Hydrocephalus
3.1.1 Clinical Representation of the Studied Patient in Family 1
The affected child was the first born to a non-consanguineous couple from
the UAE (Figure 10A). The pregnancy was uncomplicated, but ultrasound at 20
weeks of gestation revealed large head with dilated ventricles. Delivery was normal
at term with a birth weight of 3400 gm, length of 56 cm, and head circumference of
39 cm (>97th centile). There were no other reported neonatal problems. However,
family history revealed that the brother of the mother has a daughter with
hydrocephalus and ventriculoperitoneal (VP) shunt. Unfortunately, no further clinical
or radiological information were available for this child because the family refused to
participate in the research, and hence, no clinical or molecular studies were
performed on this branch of the family.
MRI brain at three months revealed widened cerebrospinal fluid (CSF) spaces
in the frontoparietal region bilaterally, as well as mild dilatation of lateral and third
ventricles (Figure 10B). The cerebral volume was preserved and the white matter
appeared normal. These findings are believed to be consistent with external
hydrocephalus.
The patient was evaluated at Tawam Hospital Genetics Clinic at the age of
nine months. His weight at the time was 10 kg (75th centile), length 77 cm (90th95th centile), and head circumference 50 cm (>97th centile; Z score 3.34). He had
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large head with frontal bossing and high arched palate, but no other dysmorphic
features. He had normal developmental milestones and at the age of 14 months he
was walking and saying a few words, but continued to have a large head. At 15
months his weight was 11.5 kg (>50th centile), height 84 cm (>90th centile) and
head circumference 51 cm (>97th centile). Detailed ophthalmological examination
was normal. Progress brain MRI at age 17 months showed less dilatation of
ventricles and less widening of CSF spaces, in line with the natural progress of
external hydrocephalus. Several clinical investigations were found to be negative,
including

microarray

for

CNVs

and

Indels,

urine

organic

acid,

urine

mucopolysaccharides (MPS), creatine phosphokinase (CPK) and skeletal survey that
were tested when the child presented with the phenotype.
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Figure 10: Clinical and molecular analysis of Family 1 with CH. A) Pedigree
showing the affected child with hydrocephalus for a non-consanguineous Emirati
family. B) MRI (T1 weighted images), upper panels at age 3 months showing
widened CSF spaces in the frontoparietal regions (white arrows), widened
interhemispheric fissure (green arrow) and mild dilatation of ventricles (red arrow).
Lower panels at age of 17 months showing improvement in the above mentioned
findings.
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3.1.2 Whole Exome Sequencing in the Affected Child Revealed Two Compound
Heterozygous Mutations in the MPZD Gene
Clinical whole-exome sequencing analysis was conducted at Baylor College
Genetics Laboratory on the affected child, it revealed two compound heterozygous
variants (c.394G>A and c.1744C>G) in the MPDZ gene. The output data from
Illumina HiSeq were converted to FastQ files by CASAVA 1.8 software, and
mapped by BWA program, the variant calls were performed using Atlas-SNP and
Atlas-indel developed in –house by BCM HGSC. The variants were interpreted
according to ACMG guidelines (C. S. Richards et al., 2008) and patient phenotypes.
For both identified variants, the minor alleles were not reported; neither in 3738
African American (AA) nor in 7017 Europeans (EA). The report included minor
allele frequency (MAF) data for variants reported in the NHLBI GO Exome
Sequencing Project (ESP) ESP5400 database to be “1/3738 1/7017” in AA/EA,
respectively. Both variants were absent in GalaxC database. Next, Sanger sequencing
was performed on the whole family to confirm the segregation of these compound
heterozygous variants with the child being compound heterozygous for both variants
(Figure 11A). The mother was heterozygous for the c.394G>A variant (Figure 11B,
left panels), while the father was heterozygous for the c.1744C>G variant (Figure
11B, right panels). The first variant (c.394G>A) has been reported as a SNP
(rs201101621) that was presumed to lead to the substitution of glycine at 132 with
serine (p.Gly132Ser). However, this SNP has a minor allele frequency of T=0.0004
based on 1000 genome, and no homozygotes were reported for this variation. In
addition,

computational

analysis

predicted

that

this

variant

is

disease

causing/damaging using Mutation Taster and SIFT/Provean software. More
importantly, this change was also predicted to cause acceptor splice site change by
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Neural Network software (www.fruitfly.org/seq_tools/splice). It predicted a score of
0.78 for the acceptor splice-site present at c.394-1G, which is one nucleotide
upstream to the variant. Furthermore, the software predicted that the variant might
lead to the use of the cryptic acceptor-splice sites within intron 5-6 with a score of
0.74, leading to skipping of exon 5 and the generation of a stop codon. We therefore
aimed to discriminate between the two possibilities as the underlying molecular
cause as illustrated in the following sections (3.1.3 and 3.1.4).
The second variant (c.1744C>G) was predicted to cause a missense mutation
at amino acid position leucine 582 to valine (p.Leu582Val). At the same locus, a
different SNP (rs201275925) has been reported with G/A alleles. This SNP has a
minor allele frequency of A=0.0002. However, the change was synonymous. In silico
analysis using Mutation Taster predicted that the p.Leu582Val variant was disease
causing. However, SIFT/Provean predicted that the change is tolerable/neutral. The
two identified variants (c.394G>A and c.1744C>G) were absent in Exome Variant
Server for all the tested population. Furthermore, there were no clearly damaging
variants in MPDZ gene in a homozygous state in normal individuals in this database,
suggesting the importance of this gene for human health. Likewise, there were no
reports of any homozygous damaging variations at the same locus in MPDZ gene in
NCBI. Additionally, analysis of the child’s WES data identified two variants in
heterozygous states in genes known to be implicated in hydrocephalus. One of which
was in CCDC88C gene (c.4327G>A) on chromosome 14, a previously reported
reference SNP (rs189215037). This variant leads to an amino acid substitution
(p.Ala1443Thr) which was predicted to be tolerated/benign by SIFT/PolyPhen-2
tools with ESP5400 AA/EA frequency of 0/3086 16/6636. The other variant was
found in KIF7 gene (c.2777G>A) on chromosome 15 which was predicted to be a
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tolerable amino acid substitution (p.Arg926Gln), but its frequency was not reported
in ESP5400 AA/EA. In addition, the variants in these two genes were heterozygous
and were not predicted to be disease-causing and therefore were excluded as relevant
to the phenotype in the child.
We wanted to further confirm the pathogenicity of the identified variants as
well as elucidate their possible underlying molecular/cellular mechanisms.

Figure 11: The chromatograms and illustration of the compound heterozygous
variants in family 1 A) Illustration of the nature of the identified variants located at
two different chromosomes (trans-configuration). B) A compound heterozygous
mutation in the child c.394G>A (left panels), inherited from his mother and a second
c.1744C>G mutation (right panels) inherited from his father. Parents are both carriers
for each mutation (Red arrows indicate the positions of the variants).
3.1.3 cDNA Sequencing Revealed a Likely Unstable Copy of the c.394G>A
Mutant mRNA
We wanted to test the predicted effect of the c.394G>A variant on mRNA
splice site; we therefore prepared and sequenced the MPDZ cDNA from the mother,
the affected child and a healthy control and in all three cases a single PCR product
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was observed (Figure 12A). In addition, Sanger sequencing revealed a single
sequencing peak (G) at position c.394 in all three cases (Figure 12B). This evidently
was different to what we observed from the genomic DNA sequencing where the
affected child and the mother were heterozygous as shown in Figure 12B (left
panels). This discrepancy can be explained by the possible activation of nonsensemediated decay (NMD) leading to rapid degradation of the mutated copy of the
mRNA but not to the wild type. This possible NMD activation could be due to the
introduction of premature stop codons in the mRNA as illustrated in Figure 12C.
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Figure 12: Chromatograms and gel electrophoresis of the amplified cDNA sequences
with the identified variants in MPDZ gene of family 1. A) PCR Amplicons of the
cDNA for the mother, healthy control, and the affected child B) Chromatograms of
cDNA from the mother, child and a healthy control, showing the wild nucleotide (G)
at position c.394 of MPDZ gene (indicated by a red arrow). C) Illustrative diagram of
both copies of MPDZ gene with the variant c.394G>A both in DNA and cDNA
sequences, explaining the results of the mother and child carrying the variant in a
heterozygous state in the genomic DNA (Top), while exhibiting only the wild type
allele (G) due to NMD mechanism (Bottom).
3.1.4 The c.394G>A Mutation Caused Skipping of Exon 5 of MPDZ cDNA
We wanted to further investigate the effect of c.394G>A on mRNA splicing,
therefore exon 5 with flanking regions of MPDZ gene have been sub-cloned into a
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mini-cassette vector used for the analysis of splicing (Figure 13, top). RNA extracted
from the transfected cells harboring wild type and mutant mini-cassette vectors were
converted into cDNAs, then they were run on agarose gel electrophoresis showing an
aberrant transcript with a molecular weight of less than 200 bps compared to the wild
type which was around 300 bps (Figure 13, bottom left). Upon sequencing both
bands, the mutant band revealed skipping of exon 5 of MPDZ, while conserving both
the vector’s exons as expected by the neural network prediction tool. The wild-type
cDNA showed the presence of exon 5 along with the vector’s exons (Figure 13,
bottom right).
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Figure 13: Illustrative model of the mini-gene analysis protocol. Patterned box depict
exon 5 and its flanking introns of the subcloned MPDZ gene, black ones depict exons
13 and 17 of 4.1R gene which was subcloned into pRc/CMV vector. Splicing of the
wild type cDNA shows the authentic splicing and the inclusion of the three exons
and that is noticed from the size of the amplified band on the gel (WT). Whereas, the
mutant cDNA (Mu) shows a smaller band due to cryptic splicing and exon skipping.
On the right side, the chromatograms represent both splice variants, dashed lines
separate the joined exons.
3.1.5 Protein Modeling of the (p.Leu582Val) Variant Indicated Possible
Disruption to the Protein Structure
The second variant (c.1744C>G) led to a missense mutation affecting a
highly conserved residue (p.Leu582Val) (Figure 14A). We therefore, carried out
molecular modeling experiments to reveal the possible structural effects of this
mutant. The images in Figures 14B and C were generated using Schrödinger Prime
and rendered using PyMOL, showing that this variant is located within the MPDZ
domain and was predicted to cause functional disruption of the domain. The mutant
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amino acid valine lies between βC and αA of PDZ4, interfering with the conserved
GLG repeat which is essential for hydrogen bond coordination of the c-terminal
carboxylate group. Moreover, as already shown in Figure 14A, the site of leucine at
this position displays evolutionary conservation consistent with the damaging nature
of the change at that position.

Figure 14: Computational analysis of the missense variant (p.Leu582Val) on MPDZ
protein A) Multiple sequence alignments for MPDZ protein among different
Eukaryotic species by Clustal Omega, shows the conservation of amino acid leucine
among selected Eukaryotic species. B) The rat PDZ4 (wild type) was used to
generate the image in PyMOL. The conserved GLG loop is shown in red with ball
and stick representation. The secondary structures (βA, βB, βC, αA, βD, βE, αB, βF)
are shown with the wild–type Leucine located between βC and αA C) PDZ4 (mutant
type). The rat PDZ4 structure (PDB ID: 4XH7) was used to generate a model of the
human PDZ4 domain using Schrodinger Prime. The mutant valine which lies
between βC and αA could disrupt or interfere with the GLG loop.
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3.1.6 Confocal Analysis Revealed that the Pathogenicity of the Compound
Heterozygous Mutations was not Due to Subcellular Localization Defects
To establish whether the pathogenicity of the amino acid substitution
(p.Leu582Val) is due to the subcellular mislocalization or trafficking defects of the
mutant protein, HeLa cells were transfected with plasmids harboring the wild type
and the mutant MPDZ cDNAs (EX-E1329-M10), Accession No.: NM_003829.4,
tagged with c-Myc-His- from GeneCopoeia (http://genecopoeia.com). In addition,
although we have shown that the c.394G>A mutation is altering mRNA splicing and
stability, we wanted to test the alternative possible implication of this variant if the
protein gets expressed (i.e. generating of a missense mutation at position
(p.Gly132Ser), we therefore generated this change using the MPDZ cDNA and then
expressed the mutant in HeLa cells, in similar fashion to the (p.Leu582Val) mutation.
The two mutants were generated using MPDZ cDNA as a template with the
following site-directed mutagenesis (SDM) primers;
MPDZ-G132S-Forward: 5`CAAAAATATGGCCCAGAGTCGCCATGTAGAAG3`
MPDZ-G132S-Reverse: 5`CTTCTACATGGCGACTCTGGGCCATATTTTTG3`
MPDZ-L582V-Forward:
5`CATTTTATCCGATCTGTTGTACCAGAGGGTCCTGTTG3`,

MPDZ-L582V-

Reverse: 5`CAACAGGACCCTCTGGTACAACAGATCGGATAAAATG3`
In all cases, HeLa cells were co-transfected with GFP-H-Ras as a plasma
membrane marker, whereas SH-SY5Y cells –neuroblastoma cell lines- were stained
with Na-K-ATPase plasma membrane marker. Since MPDZ protein is known to colocalize with synaptic markers and with tight junctions such as claudin-5 at cell
membranes (Poliak, Matlis, Ullmer, Scherer, & Peles, 2002), as well as the cytosol
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(Liu et al., 2012), cells were stained with mouse-anti-Myc-tag monoclonal antibody
(dilution: 1:200; Cell Signaling Technology) and anti-mouse IgG Fab2 Alexa Flour
555 secondary antibody (dilution: 1:200; Cell Signaling Technology). Confocal
imaging showed that the localization of the two variants is similar to that of the wild
type in both types of cells (Figures 15 and 16), thus, excluding the possibility that the
pathogenicity of either variant is caused by mis-localization of the mutant MPDZ
protein.
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Figure 15: Comparison of the intracellular localization of the wild type MPDZ
protein and both mutants in HeLa cells. A) Myc-tagged wild-type (Wt) MPDZ
protein. B) Myc-tagged (p.Gly132Ser) MPDZ protein. C) Myc-tagged (p.Leu
582Val) MPDZ protein. They were immunostained with anti Myc antibodies (red).
Cells were co-transfected with GFP-H-Ras plasmid (green) which localizes at cell
membrane. Images reveal that the wild-type protein, as well as both mutant proteins
(red) co-localize largely and similarly with GFP-H-Ras at the plasma membrane, in
addition to the solitary localization of MPDZ in the cytosol.
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Figure 16: Comparison of the intracellular localization of the wild type MPDZ
protein and both mutants in SH-SY5Y cells. A) Myc-tagged wild-type (Wt) MPDZ
protein. B) Myc-tagged (p.Gly132Ser) MPDZ protein. C) Myc-tagged (p.Leu
582Val) MPDZ protein. They were immunostained with anti Myc antibodies (red).
Cells were stained with Na-K-ATPase as a plasma membrane marker (green).
Images reveal that the wild-type protein, as well as both mutant proteins (red) colocalize largely and similarly with Na-K-ATPase at the plasma membrane, in
addition to the solitary localization of MPDZ in the cytosol.
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3.2 Endoplasmic Reticulum Retention of Xylosyltransferase 1 (XYLT1) is the
Underlying Mechanism of some Mutants Causing Desbuquois Dysplasia
type II
3.2.1 Clinical Representation of the Studied Patient in Family 2
The affected male child was born to first cousin parents of Emirati origin.
There was a history of one stillbirth at full term with similar phenotype. The child
has one normal sibling and there was no reported history of similar problem in the
extended family (Figure 17A). The child was conceived through IVF and the
pregnancy and delivery were at full term and without any notable pregnancy
complications. However, prenatal ultrasound at five months showed short long
bones. His birth weight was 2440 gm (M=3.3464, S=0.14602, L=0.3487, =>weight
z-score: -2.05), length 38 cm (M=49.8842, SD=1.8931, (L=1), =>length z-score: 6.28) and head circumference 33 cm (M=33.8787, SD=1.1844, (L=1) =>HC z-score:
-0.74)

(http://www.who.int/nutgrowthdb/about/introduction/en/index4.html

http://www.who.int/growthref/computation.pdf). At birth, the child was noted to
have short limbs, flat face and small chest. He was evaluated in the Genetic Clinic at
the age of one month. He had flat face with depressed nasal bridge, long smooth
philtrum, small mouth with thin lips and short neck. Skeletal survey at one month
showed short femurs with broadening of the proximal and distal metaphyses,
bilateral prominence of the minor trochanter ‘mild monkey wrench appearance’,
shortening of the tibia bilaterally with mild bowing and beaks at the metaphyses,
shortening and bowing of radius on both sides, the iliac bones were short and broad
with shallow acetabulum and flat acetabular roof. There was platyspondyly of the
vertebrae with sagittal clefts. There was shortening of metacarpal and phalangeal
bones with three carpal bones visible and no extra ossification center distal to second
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metacarpal. Based on these findings, a provisional diagnosis of DBQD without hand
involvement was made. Genetic study of CANT1 gene performed at Inserm
laboratories (www.idf.inserm.fr) was negative. The affected child was re-evaluated at
the age of eight years and physical examination showed a weight of 22 kg
(M=25.4163, S=0.14344, L=-0.5482, =>weight z-score: -1.05), height of 95 cm
(M=127.2651,

SD=5.6480,

(L=1),

=>height

z-score:

-5.71)

(http://www.who.int/nutgrowthdb/about/introduction/en/index4.html
http://www.who.int/growthref/computation.pdf).

He

had

dysmorphic

features

including flat face with prominent eyes, small mouth, very lax wrist joints and
interphallangeal joints, and hyperlordosis. However, he had normal developmental
milestones and was attending normal school. Skeletal survey at 8 years of age
showed similar changes as previously observed (Figures 17B, C and D)
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Figure 17: Pedigree and radiological images of the DBQD II patient of Family 2. A)
Pedigree of family 2 with a novel mutation in XYLT1 gene, displaying a first cousin
couple with the child (III-1) suffering from DBQD II (indicated with an arrow), a
second normal sib (
) and a stillbirth with similar phenotypes (
). B) The
radiological features of the DBQD type II patient with radiogram of the hip at 8 years
of age showing the mild monkey wrench appearance only in AP view, note flat
proximal femoral epiphyses and broad femoral necks. C) Radiogram of the right
lower limb at 8 years of age showing shortening of the bones, osteopenia and
beaking of metaphyses which are irregular. D) Lateral radiogram of the spine at 8
years of age showing hyperlordosis and platyspondyly of L5. Note flaring of the
metaphyses of the ribs.
3.2.2 WES and Sanger Sequencing Revealed a Homozygous Single Nucleotide
Duplication Mutation in XYLT1 Gene
To exploit next generation DNA sequencing technologies, WES sequencing
was carried out at Baylor College Genetics Laboratory on the affected child. After
filtering of the identified variants using the in-house developed softwares, a novel
homozygous variant (c.2169dupA) which resides in exon 10 of XYLT1 gene was
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identified as the main disease-causing candidate. This variant was re-sequenced in
our laboratory using Sanger sequencing on the affected child and his parents and was
found to be homozygous in the affected child and heterozygous in both parents
(Figure 18A). Bioinformatics analysis indicated that this variant was not present in
the Exome Variant Server database (http://gvs.gs.washington.edu/gvs/). However,
two more constitutional variants existed in the same data base (c.2169A>T and
c.2169A>G) (rs753887357), with protein change p.(Lys723Asn) and p.(Lys723=),
respectively, this position is pointed with a black arrow as shown in Figure 18B.
However, the minor allelic frequency of them was 0.0008% and the missense variant
c.2169A>T, p.(Lys723Asn) was predicted to have a tolerated consequence on the
protein. In addition, multiple alignments using Clustal Omega showed that the valine
residue is conserved at position 724 among multiple species (Figure 18B).
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Figure 18: Chromatograms and alignment of DNA sequence of XYLT1 in Family 2
with DBQD II affected child. A) The top chromatogram reveals the insertion of (A)
at exon 10 of XYLT1 gene in a heterozygous state in the father’s DNA. The middle
chromatogram reveals the same heterozygous insertion in the mother’s DNA and the
bottom chromatogram shows the homozygous insertion of A in the child. B) Multiple
sequence alignment of XYLT1 protein illustrating the conservation of the valine at
position 724 in red box. Arrow indicates the position of the neighboring reported
variant in the 1000 genome project.
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The inserted nucleotide, of the current study, is predicted to disrupt the
translational reading frame of the protein leading to the generation of a frame-shift
and a termination stop codon at position 733, thus deleting approximately a quarter
of the XYLT1 protein (http://web.expasy.org) (Figure 19A).
In silico analyses using MutationTaster showed that the variant is disease
causing. Furthermore, PolyPhen software predicted the variant to be possibly
damaging with a score of 0.732. The expected effects of this variant on the size of
the expressed protein was established by introducing the change into the cDNA in
mammalian expression vector then expressing the protein in HEK293T cells
followed by SDS-PAGE and Western Blotting. As predicted the size of the expressed
protein was smaller (~75 kDa) than wild type (~108 kDa) as shown in Figure 19B,
confirming truncation of the mutant protein. To further gain insight into disease
pathogenesis underlying other disease-causing mutations in XYLT1, we generated
two of the previously reported pathogenic homozygous missense mutations in
literature (c.1441C>T, p.Arg481Trp) and c.1792C>T, p.Arg598Cys) in XYLT1
cDNA (EX-E1329-M10) that was purchased from GeneCopoeia (GeneCopoeia,
Rockville, U.S.A) (www.genecopoeia.com).
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Figure 19: The In silico prediction of the variant (p.Val724Serfs*10) on XYLT1 and
the western blotting analysis of the protein. A) The amino acid sequence of the
human XYLT1 protein (www.uniprot.org) and the prediction of the variant effect
(c.2169dupA) on the protein level, showing the generation of a frame-shift at
position 724 of the amino acid sequence leading to stop after 10 amino acids, the
predicted size of the truncated protein was around 226 amino acids out of 959
(www.web.expasy.org), depicted by a blue box. B) The western blotting of XYLT1
protein from the cellular extract of HEK293T cells transfected with the wild type
(WT) or mutant (Val724Serfs*10) expression plasmids, the molecular markers on the
left show the 100, 75 and 58 kDa. The mutant protein’s molecular weight is reduced
due to the frame-shift mutation and the generation of a truncating stop codon as
predicted, whereas the other missense variants showed normal molecular weight (108
kDa).
The

following

primers

were

designed

using

PrimerX

(www.bioinformatics.org/primerx/) to generate the required mutations using
Stratagene kit (Stratagene, La Jolla, CA, USA):
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XYLT1-c.2169dupA-F:
5'GGGTGATGCCGAAAAAAAGTCTTCAAGATCGCAAG 3'
XYLT-c.2169dupA-R:
5' CTTGCGATCTTGAAGACTTTTTTTCGGCATCACCC3'
XYLT1-c.1441C>T-F: 5’ GTGGCG CCTGGGAGATTGGCGGATCCCAGAG -3’
XYLT1-c.1441C>T-R: 5’ CTCTGGGATCCGCCAATCTCCCAGGCGCCAC-3’
XYLT1-c.1792C>T-F: 5' CCTACCTTCTTTGCCTGCAAGTTTGAAGCC 3'
XYLT1-c.1792C>T-R: 5' GGCTTCAAACTTGCAGGCAAAGAAGGTAGG 3'
The generated constructs were sequenced by Sanger sequencing to confirm
the introduction of the desired mutations (Figure 20), and expressed in HEK293T
cells and their extracts were run on SDS-PAGE and probed with Anti-XYLT1 rabbit
polyclonal antibody (dilution: 1:500; Sigma). This showed a truncated protein for our
novel mutant while the other generated missense mutations (c.1441C>T,
p.Arg481Trp and c.1792C>T, p.Arg598Cys) exhibiting the expected molecular
weight (Figure 20B)
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c.2169dupA

c.1441C>T

c.1792C>T
Figure 20: The chromatograms of the XYLT1 cDNA (EX-E1329-M10) plasmid
mutated by SDM to generate the desired variants, the sites of mutagenesis are
indicated in red arrows
3.2.3 Confocal Microscopy Suggests ER Retention as a Cellular Mechanism
Underlying Several XYLT1 Mutants Causing DBQD Type II
The subcellular localizations of the generated XYLT1 mutants were
established by confocal immunofluorescence staining of the transfected HeLa cells,
using polyclonal antibodies directed towards the XYLT1 protein (Anti-XYLT1

91
rabbit polyclonal antibody (dilution: 1:50; Sigma). As expected, the wild type
XYLT1 protein localized predominantly to the Golgi apparatus as evidenced by its
extensive co-localization with the Golgi marker Golgin-97. In contrast, the three
tested mutants (p.Val724Serfs*10, p.Arg481Trp and p.Arg598Cys) did not colocalize with this Golgi marker but showed a more extensive reticular pattern
suggesting ER retention (Figure 21). We therefore, co-stained the expressing cells
with the well-established ER marker (Calnexin) which showed that the three mutants
are largely co-localizing with it in contrast to wild type (Figure 22) suggesting
trafficking defects of the mutant proteins and their retention by ER protein quality
control mechanisms.
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Figure 21: Immunoflourescence staining of HeLa cells transfected with c-Myc-Histagged XYLT1 plasmids. A) The wild type (WT) XYLT1, B) The proband variant
p.(Val724Serfs*10), C&D are the two reported mutations p.(Arg481Trp) and
p.(Arg598Cys), respectively. They were probed with rabbit polyclonal anti-XYLT1
antibodies and merged with the Golgi marker (Golgin 97) showing mis-localization
from Golgi and retention in ER in all mutants compared to their wild counterpart
which shows high localization of the enzyme in Golgi, but less in ER.
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Figure 22: Immunostaining of HeLa cells transfected with the same plasmid and
generated mutations using anti-XYLT1 antibodies and anti-Calnexin as an ER
marker to compare the subcellular localization of the wild and mutant proteins in
cells. A) XYLT1 of WT is predominantly localized in Golgi with some cells showing
localization in ER (Not shown here) since XYLT1 is synthesized in the ER but exerts
its catalytic function at Cis-Golgi. However, (B, C and D) all mutants demonstrated
exclusive localization at the ER.
To examine the correlation of the two color channels of the tagged-XYLT1
with the different cellular markers in real image data, co-localization test of the
above images was applied, and the degree of localization was plotted in scatter-plot
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graphs, confirming the co-localization of the wild type XYLT1 with Golgin 97
marker, whereas all the mutants co-localized with Calnexin (ER marker) (Figure 23).

Figure 23: Co-localization test with Pearson and Mander’s scatter-plot and
correlation coefficients. Plots on the left panel correspond to co-localization of
XYLT1 with the golgi marker (Golgin 97). Right panels correspond to the colocalization with the ER marker (Calnexin). Wild-XYLT1 proteins show complete
co-localization with Golgin 97, resulting in a straight slope with Pearson Coefficient
(PC) close to 1, compared to calnexin slope (PC<0). While the three mutants show
full co-localization with the Calnexin (PC=1), and exclusion of the signal with
Golgin 97 (PC<1).
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3.2.4 XYLT1 Protein is Most Likely Insensitive to Glycosidase Enzymes
The confocal studies proved the mis-localization of the mutant XYLT1 and
their retention into the ER compared to the wild type XYLT1 which were shown to
localize at the Golgi. We therefore wanted to further support this conclusion by
testing their resistance/sensitivity to glycosidase enzymes. Wild type XYLT1 should
ideally contain hybrid or complex oligosaccharides moieties, and hence should be
resistant to Endoglycosidase H (Endo H). Whereas the mutant forms should only
harbor high mannoses or even simpler forms of oligosaccharides which are sensitive
to Endo H. We selected two of the glycosidase enzymes that could indicate the
subcellular localization of proteins. Endo H and peptide N-glycosidase F (PNGase F)
which can cut most types of glycoproteins. The immunoprecipitated wild type and
mutant proteins were digested by Endo H which cleaves high mannose and hybrid
oligosaccharides, but not complex ones. Figure 24A depicts the results of Endo H
treatments on immunoprecipitated XYLT1 proteins, showing the resistant pattern of
the wild type and mutant proteins despite the fact that all mutant XYLT1 were
retained in ER, proved by confocal studies. That could be explained by the fact that
glycoproteins are resistant to endo H digestion if they have the antennae-like
structure (core structure), lacking the three linear mannoses (Man1α3Man1α6Man1β)
shown in Figure 25, even if reactions are driven with high enzymatic concentrations,
which are essential components that determine the specificity of endo H and endo F2
enzymes (Trimble & Tarentino, 1991). Thus, we further carried out digestion with
PNGase F enzyme, which is known to digest the bond between GlcNAc and
asparagine (Asn), releasing the whole carbohydrate from the protein (Figure 25). It is
well established that PNGase F can digest complex glycans (Golgi forms) (Freeze &
Kranz, 2010). The proteins were exposed to PNGase F, and were run on SDS-PAGE.

96
Intriguingly, neither the wild-type, nor the mutants showed any shift in the size of
their protein bands, except for the positive control, which is a reported mutated
endoglin protein (p.Pro165Leu) with established ER retention and sensitivity to endo
H (Ali et al., 2011), suggesting resistance of all XYLT1 proteins to PNGase F,
consequently to all glycosidases (Figure 24B). We concluded that the resistance of
XYLT1 proteins to PNGase F might be attributed to the location of the Nglycosylation sites on XYLT1 proteins, and probably if the reaction was left under
extended incubation times (three days or more) could have shown effect on the
proteins, however, such conditions would possibly affect the activity of the enzyme
or the stability of the proteins. Moreover, another explanation for the resistance is
that XYLT1 protein has only three glycosylation sites, and left with only two in the
truncated one (p.val724fs*10), and it has been shown that the average size of the
carbohydrate chain in glycoproteins ranges between 1.5-3 kDa (Freeze & Kranz,
2010), which in our proteins ranges from 3-9 kDa, and this difference in sizes
between the cut and the uncut forms cannot be easily demonstrated by western
blotting. Therefore, it can be deduced from these experiments that the glycosidase
test may not be applicable to assess the mis-localization of the mutant proteins in the
subcellular compartments as the confocal studies did.

Figure 24: The Western blot of the glycosidase tests performed on XYLT1 proteins. A) Endo H assay of the wild-type XYLT1 and the generated
mutants, all plasmids were transiently expressed in HEK293T cells, immunoprecipitated, then incubated in the presence of Endo H (+) or without
Endo H (-) for 4 hours at 37 ºC. All proteins showed no susceptibility to Endo H digestion, except for the positive control. B) PNGase F
susceptibility test of the wild-type and mutant XYLT1 whole cell lysates with the presence (+), or absence (-) of PNGase F for 24 hours at 37 ºC.
All proteins (except positive control) showed resistance to the de-glycosylation effect of PNGase F.
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Figure 25: Symbolic structures of the N-linked carbohydrate chains of the glycoproteins showing the specificities of the endo H and
PNGase F enzymes. The sensitivities are depicted by (+), whereas the resistant forms by (-). Endo H enzyme cannot cleave the core
structure that lacks (Man1α3Man1α6Man1β) as well as the complex structures. However, PNGase F can cut all forms except for the α1,3
fucose moieties.
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3.3 Identification of TSHZ3 and CRTAC1 as Possible Candidate Genes in
Monogenic Intellectual Disability Syndromes
3.3.1 Clinical and Molecular Assessment of the Patients in Family 3
Two daughters born to a Pakistani consanguineous couple were diagnosed
with microcephaly, severe ID, and muscle hypotonia (Figure 26). The family history
revealed two other children with similar phenotype. However, we were unable to
assess them in this study. The first affected child for the couple is a female who is a
product of normal pregnancy and delivery. Birth weight was 3 kg but no head
circumference measurements were available as she was born in Pakistan. There were
no noticeable major neonatal problems. However, in the first few months of life, the
mother noted that she was very irritable and crying all the time and unable to sleep.
She was evaluated by a doctor who told the mother that she had small head
circumference measurement. She was evaluated at Tawam Hospital Genetics Clinic
at the age of 6 years. She had severe delay in all milestones with no speech or
interaction with the mother. She was unable to walk but can sit alone and rocks her
body forward and backward all the time. However, her weight and height were
appropriate for her age and no dysmorphic features. Her head circumference at the
age of 6 years was 46 cm (-5 SD). Neurological examination was normal. She had
myopia and squint for which she wears glasses. Metabolic screening of very long
chain fatty acid and phytanic acid as well as microarray analysis were normal.
Child 2 is the sister of the first patient. She was the product of normal
pregnancy and delivery but, unfortunately, no birth measurements were available.
She was similar to her sister in terms of developmental deficiencies. Evaluation at 4
years of age revealed normal weight and height, but she had small head with HC of
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44 cm (-6 SD). She had severe developmental delay with no dysmorphic features or
neurological abnormalities.
We next performed whole-genome SNP genotyping for all the available
family members (ATLAS Biolabs, GmbH, Germany, www.atlas-biolabs.com). This
genotyping was performed using the Genome Wide Affymetrix SNP 6.0 genotyping
assay which detects around 900K SNPs and 900K CNV markers. In addition,
concurrently we performed WES which was carried out at Sengenics Inc, Kuala
Lumpur, Malaysia (www.sengenics.com) using the Illumina HiSeq 2500 platform.

Figure 26: The pedigree of a highly inbred Pakistani family, the studied branch (family 3) showing consanguineous parents with the two affected
daughters by microcephaly, ID, and muscle hypotonia, arrow indicates the proband
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3.3.1.1 Homozygosity Mapping Identified Several Blocks of Homozygosity
across the Genome
The genome-wide SNP data (calls) for the whole family were uploaded into
the homozygosity mapper software (www.homozygositymapper.org). The used chip
was selected, and the analyzed patients’ IDs were entered as cases, whereas the
healthy were entered as controls. The resulting graphical interfaces were obtained
from GeneDistiller, and they showed five homozygous stretches of widths ranging
from 6.8-27.8 Mbs, they were located in chromosomes 7, 9, 12, 14 and 19 (Figure
27). The largest stretch of 27.8 Mbs was located in chromosome 12. The second
largest homozygous stretch was mapped on chromosome 19 (22.5 Mbs), followed by
chromosome 7 which harbored a stretch of 22 Mbs. The fourth stretch was located on
chromosome 9 (6.8 Mbs) and the smallest stretch of 5.6 Mbs was mapped on
chromosome 14 as shown in Table 2. In this table, the loci of the homozygous
regions and the SNPs at which they start and end are listed.
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Figure 27: The homozygosity map of (Family 3) harboring five homozygous regions
depicted by red bars. Homozygosity scores are displayed as a genome-wide bar
chart. Scores higher than 80% of the maximum score are displayed as red bars,
indicating homozygous regions which are found in the affected, but absent in the
non-affected members. Smaller decreases of the score within a homozygous region
are neglected (black bars). Homozygosity is detected in chromosomes 7, 9, 12, 14
and 19.
The length of each red bar (homozygous regions) as well as the reference
SNPs flanking each homozygous region are illustrated in Table 2.
Table 2: Locations and widths of the homozygous regions in family 3
From
(bp)

To (bp)

5.5

132405157

137911594

rs481158

rs2352478

16.7

137920895

154663549

rs10272694

rs11768385

9

6.8

134243090

141071475

rs9328529

rs7863719

12

13

20371195

33429249

rs4335623

rs10844528

14.8

33447503

48317832

rs11052596

rs7311030

14

5.6

25609273

31245971

rs7144438

rs911088

19

22.5

31343455

53910518

rs10402875

rs2061771

Chromosome
7

Distance
(Mbs)

From SNP

To SNP
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3.3.1.2 WES Analysis Identified Six Candidate Variants as Potential Cause of
the Phenotype in Family 3
WES analysis was conducted on the two affected siblings to identify novel
candidate genes that might be responsible for the phenotype in family 3, we
established an integrated WES data filtering approach aiming first to extract essential
variants calls such as missense, stop gained, frameshifts and splice-site variants, thus
excluding intronic and synonymous ones. More than 700,000 variants were obtained
from the WES data performed on the two affected daughters of family 3 that got
reduced to 25,000 upon following the filtering criterion. The filtration was conducted
by Al-Jezawi N.K at the Pathology Laboratory in the UAE University.
Upon filtering SNP data, only variants encountered within the homozygous
regions generated by the homozygosity mapper were included in the subsequent
analysis. After excluding the variants outside the mapped region, the number of
variants was narrowed down to around 400. Furthermore, the variants which were in
dbSNPs, 1000 Genome, Exome Variant Server, or ExAC browser or any other
database were excluded. Additionally, variants with allelic frequency more than 0.01
were excluded, resulting in decreasing the number to around 250 variants. After we
excluded the variants not detected among both affected members, the number of
candidates was narrowed to around 100 variants. The remaining candidates were
then studied extensively using other bioinformatics tools, assessing their expression
profiles, cross-checking with published data on their mutations and diseases using
HGMD, the number reduced to 10-20 candidate genes. The final step was
performing segregation analysis by Sanger sequencing on all the family members to
define their genotypes. Summary of the results of this filtering strategy are shown in
Figure 28.
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Figure 28: The filtration pipeline used in this study to analyze and prioritize the WES
data for Family 3 with the number of variants resulting from each step
Various studies have shown the involvement of several genes in the
pathogenesis of microcephaly, hence, these genes were cross-checked in both
patients to look for any damaging variants and were ruled out. For example, in STIL
gene, one damaging homozygous missense variant (c.3515C>T, p.Ser1172Phe) was
detected in the patients, however, the gene was excluded because it did not segregate
with the phenotype among all the family members. Other microcephalic known
genes (MCPH1, ASPM, WDR62, CDK5RAP2 and CASC5) were as well excluded
due to their high minor allelic frequencies (GMAF), ranging from 0.22 to 0.99. In
addition to their tolerated/benign nature, and the presence of a large number of
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individuals carrying the same variants in homozygous states. For example, in ASPM,
one identified variant (p.Tyr2494His) was found to have allelic frequency of 0.999 in
ExAC database with 60,051 individuals carrying the same variant in a homozygous
state. Moreover, the remaining genes known to be implicated in microcephaly were
not detected within the mapped region in our patients.
The number of potential candidate genes after this filtering analysis was six,
including variants in OR2A14, ENTPD8, LRRK2, EML2, TSHZ3, and HKR1 genes.
Segregation analyses using Sanger sequencing of those variants are shown in Table
3, indicating that the variant in OLFM1 gene can be excluded because it did not
segregate with phenotype in the family. On the other hand, the variants in the other
genes segregated and they were all causing missense mutations except for the frameshift variant in LRRK2 gene (c.4325_4327delCTT) that led to deletion of alanine at
position 1442 out of 2527 amino acids.
Table 3: List of the candidate variants in genes for the clinical phenotypes of
Family 3
Chr.

Gene

Distance
(Mbs)

Position

DNA change

Protein Segregation
change

7

OR2A14

22.2

143826206143827138

c.725C>T

p.S242F

YES

9

ENTPD8

6.8

140328816140335901

c.505G>A

p.G169S

YES

9

OLFM1

6.8

137967089138013030

c.358_359insA

p.W129*

NO

12

LRRK2

27.8

4061881340763087

c.4325_4327delCTT

AS/S

YES

19

EML2

22.5

4611265846148775

c.2543G>A

p.R848Q

YES

19

TSHZ3

22.5

3176585131840190

c.755A>G

p.K252R

YES

19

HKR1

22.5

3782558037855357

c.1628G>A

p.G543E

YES
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3.3.1.3 Further Analyses to Test the Candidacy of the Identified Variants
In theory only one of those variants could be responsible for the observed
phenotype and we therefore needed to carry out further detailed analyses to exclude
or confirm the pathogenicity of individual variants. This included bioinformatics
analyses, and in some cases functional assays.
Bioinformatics and in silico Analyses Identified the Variant in TSHZ3 Gene as
the Strongest Candidate for the Phenotype in this family
Each identified variant within the candidate genes was evaluated for its
population allelic frequency in different publically available databases, in addition to
other bioinformatics tools illustrated in Table 4.
All the variants in the identified genes were not found in the exome variant
server

(http://gvs.gs.washington.edu/gvs/)

and

Galax

C

(www.galaxc.sengenics.com), furthermore, their allelic frequencies were very low
according to ExAC database (www.exac.broadinstitute.org). However, the two
variants in EML2 and TSHZ3 genes were found in the 1000 Genome Project database
(www.browser.1000genomes.org), albeit in the heterozygous states.
The protein effect prediction showed variability according to the nature of the
variant, and most of the expression profiles of the identified genes were found to be
abundant in many tissues (Table 4).
As already mentioned, we were able to identify a few candidate variants that
might be responsible for the phenotypes in family 3. While only two candidates
(TSHZ3 and LRRK2) were among the most reliable, the remaining were excluded,
although not experimentally analyzed, as described in the following paragraphs. First
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of

all,

ENTPD8

gene

which

stands

for

Ectonucleoside

Triphosphate

Diphosphohydrolase 8 enzyme and which has a nucleotidase activity as shown in
animal models (Fausther et al., 2007), was not considered as a strong candidate
because

we

found

three

(http://gvs.gs.washington.edu)

normal
carrying

individuals
a

in

damaging

genomic
variant

at

databases
position

(p.Gln166Argfs*88) leading to a truncation of 254 amino acids out of 495,
additionally, another homozygous damaging variant (p.Leu301Profs*7) was present
in a homozygous state in 33 normal individuals (www.evs.gs.washington.edu),
suggesting that this gene might be dispensable in humans. Besides, the phenotype in
our patients is mainly neurological, ENTPD8 protein is a liver-enriched enzyme
responsible for regulating nucleotide concentration extracellulary, and is mainly
expressed in gastric tissue as shown in Table 4, and therefore this gene is unlikely to
be implicated in disease primarily affecting the brain. In addition, we would expect
effects on the gastric system rather than neuronal.
Moreover, EML2 (EMAP2) gene was excluded because we found five normal
individuals carrying probably damaging variants in the homozygous states
(p.Arg558His) and another probably damaging homozygous missense variant
(c.Leu388Phe) in 145 normal individuals (www.evs.gs.washington.edu). In addition,
EML2 protein although abundantly expressed as shown in Table 4, has different
splice-variants with different expression patterns (Lepley, Palange, & Suprenant,
1999). EML2 is a microtubule-associated protein that has 65% homology with
EMAP1, the latter being a strong candidate of Usher syndrome 1a locus, giving this
group of proteins a possibility of being involved in human diseases in general (Eudy
et al., 1997). As Table 4 indicates, the identified variant in EML2 gene (c. 2543G>A,
p.Arg848Gln) was predicted to be a polymorphism by Mutation Taster. The same
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prediction applied on HKR1 gene, an oncogene that might be involved in
transcriptional regulation (www.pathcards.genecards.org). As shown in Table 4,
there exists two possibly damaging missense variants in a homozygous state
(p.Arg448His and p.Gly28Arg) the first one found in 58 normal individuals out of
5546 and the second was found in two individuals out of 6410. On the other hand,
the two frame-shift variants (p.Leu594Hisfs*2 and p.Thr436Argfs*15) reported in
one and three individuals, respectively were very close to our variant (p.Gly543Glu).
mRNA of HKR1 was found to be highly expressed in lung tissues and was suggested
to be involved in lung cancer progression and in mitogen-activated protein kinase
(Oguri et al., 1998).

Table 4: Bioinformatics and computational analyses on the identified candidate variants in Family 3
Gene

Exome
Variant
Server

Exac
AF

Mutation
Taster

Sift/PolyPhen

FATHM
M

Homo.
states

1000G

Galax
C

Cons

Expression

ENTPD8

None

0.000008

Disease causing

Deleterious/Possibly
damaging

Tolerated

2 frame-shift
variants

None

None

YES

Colon, small
intestine, liver,
pancreatic juice &
testis

EML2

None

0.0001

Polymorphism

Deleterious/Possibly
damaging

Tolerated

2 Missense
variants

Het:6

None

P

Abundant.
Overexpressed in
salivary glands &
peripheral blood

LRRK2

None

NA

Disease causing

-

-

4 Missense
variants

None

None

P

Overexpressed in
Nervous system,
adrenal gland &
kidney

TSHZ3

None

0.00019

Disease causing

Tolerated/Probably
damaging

Tolerated

None

Het:1

None

YES

Abundant,
overexpressed in
liver

HKR1

None

0.00009

Polymorphism

Tolerated/Probably
damaging

-

2 Missense &
2 Frame-shift

None

None

YES

Abundant,
overexpressed in
islets of langarhans

OR2A14

None

NA

Disease causing

Deleterious/Probably
damaging

Tolerated

None

None

None

YES

Highly expressed in
heart

Homo: Homozygous; Cons: Conservation; P: Partially conserved.
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OR2A14 gene, on the other hand, encodes a protein responsible for the
perception of smell. This gene was selected among candidates assumed to play a role
in the high-altitude pulmonary edema occurring in healthy Chinese who ascend to
altitudes exceeding 2500 m above sea levels (Yang, Wang, Xu, & Ge, 2017). Despite
the fact that all the above genes segregate with the phenotype in family 3, their
expression profiles, protein function and the reported phenotypes make them less
likely candidates for the phenotype in this family.
Based on this analysis, we can conclude that Teashirt Zinc Finger Homeobox
3 Gene (TSHZ3) and Leucine Rich Repeat Kinase 2 (LRRK2) genes are the strongest
candidates for the phenotypes in family 3. This conclusion is based on the following
observations. The variant (c.755A>G) described, causes a novel homozygous
missense mutation (p.Lys252Arg) in TSHZ3. The variant was located in one of the
biggest homozygous regions (22.5 Mbs). Segregation analysis revealed both affected
daughters to be homozygous, while parents showed heterozygous states (Figure 29).
Protein prediction tools such as Mutation Taster showed that the variant was diseasecausing. The variant was absent from the exome variant server and with low allelic
frequency in ExAC (0.00019). In the 1000 genome project, one individual was found
to carry the variant but in a heterozygous state. Experimentally, some animal models
showed loss of viscerocranium upon knockdown of the gene, causing defects in the
development of the face and brain in zebra fish (Melvin, Feng, Hernandez-Lagunas,
Artinger, & Williams, 2013). In other studies, some microcephalic patients were
presented with deletion in TSHZ3 gene (Caubit et al., 2016). Besides, TSHZ3 gene is
abundantly expressed in brain cortex, which is the main part of the brain affected in
microcephaly (Kajiwara et al., 2009). Based on these functional assays we have
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designed several experiments in an attempt to provide further evidence on its
responsibility for the observed phenotype in this family.

Figure 29: The chromatogram of DNA sequence of the variant (c.755A>G) in TSHZ3
gene of Family 3 showing the heterozygous states of the parents and the homozygous
states of the mutant variant in both affected children.
Functional Analyses could not Confirm or Exclude the Pathogenicity of
TSHZ3 Variant
TSHZ3 is a protein that contains 3 zinc finger motifs in its N-terminal half (2525-19 amino acids) and a homeobox domain that binds DNA (71 amino acids) and
two additional zinc finger motifs in its C-terminal half (23-24 amino acids) (Faralli
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et al., 2011). The identified variant (c.755A>G) lies between two zinc fingers
responsible for the binding of this protein with Histone deacetylases 1 and 2
(HDACs 1 and 2) (Figure 30).

Figure 30: Schematic representation of the TSHZ3 protein with its domain structure
and the relevant binding sites
I therefore, decided to examine the effects of this variant on binding with
HDACs. Chromatin immunoprecipitation experiments showed a direct interaction of
FE65, a protein which binds to the intracellular domain of the beta amyloid precursor
protein (PP), and TSHZ3 with the promoter region of CASP4 gene. FE65 could
simultaneously recruit SET, a component of the inhibitor of acetyl transferase, which
in turn recruits histone deacetylases, to produce a powerful gene-silencing complex.
Reduced expression of TSHZ3 mediated by genetic or other causes is likely to
increase CASP4 expression, leading to progression of Alzheimer’s Disease (AD)
(Kajiwara et al., 2009) (Figure 31).
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Figure 31: Model showing the network of genes responsible for the suppression of
CASP4 expression with TSHZ3 playing a pivotal role
I hypothesized that the identified variant in TSHZ3 which is located between
two zinc fingers of TSHZ3 protein could alter its suppressive effect on CASP4 gene
expression by affecting HDACs binding. Therefore, the mutant and the wild type
TSHZ3 plasmids (Myc-DDK-tagged human TSHZ3) (OriGene, USA) were
expressed in HEK293T cells, co-immunoprecipitated with Anti c-Myc-Agarose and
probed with Anti HDACs 1 and 2 to assess the effect of the variant on these proteinprotein interactions. The western blotting assay showed that both the wild type and
mutant TSHZ3 proteins are still able to bind HDACs 1 and 2 as shown in Figure 32.
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Figure 32: Pull-down assay of both wild type and mutant Myc-tagged-TSHZ3
proteins shows interaction with HDAC1 and 2. HEK293T cells were transfected with
either wild type or mutant TSHZ3 cDNA, expression of TSHZ3 and HDACs 1 and 2
was confirmed by blotting whole cell extract (input). Co-immunoprecipitation of
TSHZ3 was performed by Anti-Myc slurry, then they were probed with Anti HDACs
1 and 2 separately, all normalized against GAPDH.
We also carried out quantification analysis of CASP4 expression in patient’s
fibroblasts. This was to examine the suppressive function of TSHZ3 on the
expression of CASP4 gene in order to fully understand the downstream suppressive
effect of TSHZ3. Therefore, patient’s total RNA was isolated from skin fibroblasts,
and reverse transcribed using designed TaqMan probes that hybridized on cDNA as
described in the methods chapter. Comparative quantification was performed on one
of the daughter’s sample against multiple control samples to assess the change in
expression of CASP4 gene. The target gene in this experiment was normalized
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against two house-keeping genes (GAPDH and HPRT). The CT values of the patient
were measured in comparison with the CT values in multiple healthy controls. The
expression of CASP4 in the patient sample appeared to be unchanged compared to
the controls with a p-value of 0.1235 (Figure 33).

Figure 33: Real-time PCR demonstrates that the expression of CASP4 by the
fibroblasts of patient 2 from Family 3 shows no significant change compared to
seven healthy controls
As explained earlier, the second strongest candidate gene was LRRK2. This
multi-functional domain protein lies in the biggest homozygous stretch in this family,
spanning a region of 27.8 Mbs. The detected variant (c.4325_4327delCTT) was
predicted to lead to alanine deletion at position 1442. The protein shows high
variability of expression in different tissues, however, the highest scored was in the
nervous tissue (score=4.6) (www.genecards.org), and specifically in the cerebellum
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and cerebral cortex (www.uniprot.org). The variant was not found in any of the
investigated databases and it was predicted to be disease causing. However,
homozygous missense variants were detected in normal individuals, where one of
them (p.Asn551Lys) was not located within an essential domain. Compared to the
identified variant in the current study (p.Ala1442del), the deletion was expected to be
deleterious of a high score (-10.546), cut off value (-2.5) by Provean software
(www.provean.jcvi.org).
The identified variant segregated with the phenotype in family 3 as shown in
Figure 34.
Our main conclusion from these results is that TSHZ3 gene cannot be
excluded as a potential cause of the phenotype in family 3. The results as given in
Figures 32 and 33 did not support our proposed hypotheses, hence, further
justification of our conclusion can be achieved by proposing convincing assays that
will address the issue and can effectively draw a conclusion about the association of
the identified gene in the studied family. Furthermore, LRRK2 is as well a strong
candidate gene. However, the knowledge and validation of its attribution to the
phenotypes are acquired by further functional and experimental analyses that could
be implemented for the future perspectives of this study. The future research
objectives could be expanded to include further experimental approaches that can
give the opportunity to include or exclude the candidate genes.
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Figure 34: The chromatogram of DNA sequence of the variant (c.4325_4327delCTT)
in LRRK2 gene of Family 3 showing the heterozygous states of the parents and the
homozygous states of the mutant variant in both affected children
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3.3.2 Clinical and Molecular Assessment of the Patients in Family 4 revealed
CRTAC1 as a Candidate Gene
In this family, two children affected by intellectual disability, dysmorphic
features and anorectal anomalies, and two healthy were born to a consanguineous
Palestinian couple living in the UAE (Figure 35A). The proband is a female (III-4 in
the pedigree). She is the product of normal pregnancy and lower segment cesarean
delivery (LSC) due to fetal distress. Her birth weight was 3700 gm. There were no
significant neonatal problems. She smiled at 2 months and responded to mother.
However, there was no further progress in development. At 7 months of age, the
mother noted that the child was hypotonic. Evaluation at 1 year of age showed a
dysmorphic child with hypotonia and head lag, joined eyebrows, depressed nasal
bridge, short nose, long smooth philtrum, thin upper lip with downturning corners,
overlapping toes. She was unable to sit or bear weight on her leg. She had difficulty
in swallowing and was on pureed food only. No seizures were reported. She had a
similarly affected 12 years old brother (III-1 in the pedigree). He had anorectal
malformation diagnosed at birth which was operated on. He is severely intellectually
disable with similar dysmorphic features like his affected sister.
To exclude CNVs or any other structural aberrations in the proband’s
chromosomes, CGH microarray was performed at Sengenics, Kuala Lumpur,
Malaysia (www.sengenics.com) on the patient (III-1). The result of CGH was
negative. As a next step, SNP genotyping for the whole family was performed at
ATLAS Biolabs, GmbH, Germany (www.atlas-biolabs.com) using Genome Wide
Affymetrix SNP 6.0 genotyping assay. WES was performed at Sengenics, Kuala
Lumpur, Malaysia (www.sengenics.com) using illumina HiSeq 2500 platform.
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3.3.2.1 Homozygosity Mapping Identified Blocks of Homozygosity across the
Entire Genome
The genome-wide SNP data (calls) for the whole family were uploaded in the
homozygosity mapper software (www.homozygositymapper.org). The used chip was
selected, and the analyzed patients’ IDs were entered as cases, whereas the healthy
were entered as controls. The resulting graphical interfaces were obtained from
GeneDistiller, and they showed 11 significant homozygous stretches located in
chromosomes 4, 5, 7, 8, 10, 12, 13, 14, 15, 16 and 18. The largest stretch was located
in chromosome 14 with a width of 18.5 Mbs (Figure 35B).
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A

B

Figure 35: The pedigree and the homozygosity map of family 4 A) The pedigree
shows two siblings affected by ID and dysmorphic features and two other healthy
siblings, for a consanguineous parent. B) The homozygosity map shows the
homozygosity scores displayed as a genome-wide bar chart. Scores higher than 80%
of the maximum score are displayed as red bars, indicating homozygous regions
which are found in the affected, but absent in the non-affected members. Smaller
decreases of the score within a homozygous region are neglected (black bars).
Homozygosity is detected in chromosomes 4, 5, 7, 8, 10, 12, 13, 14, 15, 16 and 18.
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3.3.2.2 WES Analysis Identified Variants in Six Candidate Genes for the
Phenotype in Family 4
After performing genome-wide SNP genotyping on all family members, the
generated homozygosity map showed homozygous regions across the genome
inherited from common ancestors. We applied WES on the affected siblings, the
previously applied WES pipeline filtering suggested the candidacy of six genes
harbouring biallelic variants within the long runs of homozygosity in the patients,
segregating with the phenotypes. Table 5 lists the candidate genes and their
corresponding homozygosity blocks along with the variants identified.
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Table 5: A list of all candidate genes which are likely associated with the clinical
phenotypes in Family 4
Chr

Gene

Distanc
e (Mbs)

Position

DNA
change

Protein
change

Segregation

7

KMT2C

13.5

2079210734334957

c.2447ins
T

p.Ile817Hisf NO
s*11

7

KMT2C

15.3

111625713
126948370
-

c.871C>T

p.Leu291Ph
e

NO

7

KMT2C

10

148258161
158279130

c.2512G>
A

p.Gly838Sr

NO

7

GIMAP2

10

148258161
158279130

c.53C>A

p.Ala18Asp

NO

7

PDE1C

13.5

2079210734334957

c.280T>C

p.Ser94Pro

NO

10

CRTAC1

13.7

94538960108272675

c.1798G>
A

p.Glu600Ly
s

YES

14

NRXN3

18.5

7489959293423431

c.1648C>
G

p.Leu550Va
l

NO

18

DSC3

15.4

2845927943885435

c.1551T>G

-

NO

*Chr: Chromosome.
3.3.2.3 Sanger Sequencing Revealed a Possible Deleterious Segregating Missense
Variant in Cartilage Acidic Protein 1 (CRTAC1) Gene
Sanger sequencing performed on all the family members for the listed
candidate genes confirmed WES findings for CRTAC1 gene exclusively. Both
probands demonstrated a homozygous change (c.1798G>A, p.Glu600Lys), whereas
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both the father and the mother were carriers. Child 2 (healthy sib), was homozygous
to the wild type (GG), while child 3 (healthy sib) was heterozygous (Figure 36).

Figure 36: The chromatograms of the DNA sequence of the variant (c.1798G>A) in
CRTAC1 gene. The father (F) and the mother (M) show heterozygous pattern (R),
while the affected Children (C1, C4) are homozygous to the variant (AA). Children 2
and 3 (C2, C3) are healthy sibs showing wild type (GG) and heterozygous (R),
respectively.
The variant was predicted to be disease-causing and deleterious by Mutation
Taster and SIFT softwares, respectively. It was also predicted to be damaging by
FATHMM with a score of (-2.99). Furthermore, segregation analysis for all the
remaining variants showed no linkage with the phenotypes among all family
members. Hence, all the other genes were excluded from this analysis. CRTAC1 gene
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is located in chromosome 10 and is overexpressed in in bladder, artery, tibia, CSF,
cartilage, synovial fluid, brain cortex and fetal brain (www.genecards.org). The
variant was absent in the exome variant server with no damaging variants existing in
homozygous states in CRTAC1 gene. However, one homozygous variant existed in
ExAC database with very low allelic frequency (0.00006). In the exome variant
server, one probably damaging variant (p.Val569Met) existed in 3 individuals out of
6216. Figure 37 shows the conserved nature of glutamate (E) among multiple species
at the identified position.

Figure 37: Multiple species alignment showing the conservation of the wild type
amino acid (E) observed in CRTAC1 gene
In conclusion, both the bioinformatics and segregation analyses provided
moderate evidence that the variant identified in CRTAC1 gene could be causal to the
phenotypes of the affected children in family 4. In order to elucidate whether the
gene is directly involved in the pathogenesis of the disease, experimental, animal or
human models (well-phenotyped patients) should be carried out.
To further confirm the pathogenicity of the identified variant in CRTAC1
gene, we have submitted those variants to the gene matcher data base
(www.genematcher.org) to share our discovered genes and variants with world-wide
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researchers and clinicians in order to find other families around from other parts of
the world who share similar phenotypes and genes. We also submitted TSHZ3 and
LRRK2 genes as potential causes of ID.
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Chapter 4: Discussion
In this study we have performed genomic and cellular experiments in order to
establish the molecular and cellular mechanisms of autosomal recessive disorders in
families residing in the UAE. It is expected that such autosomal recessive disorders
are caused by biallelic mutations in genes encoding proteins involved in vital
functions in human. These disorders appear to be Mendelian and therefore could be
identified and proved by different genetic analyses.
Robust and state of the art genetic approaches have been applied here in an
attempt to elucidate mechanisms, include, or exclude candidate genes. As
hypothesized, consanguineous and highly inbred families offer tremendous potentials
to discover novel causative genes and mutations believed to be responsible for
recessive phenotypes, in a way to achieve precise diagnosis and assist in integrating
preventive programs.
4.1 Compound heterozygous variants in the multiple PDZ domain protein
(MPDZ) cause a case of mild non-progressive communicating
hydrocephalus
Hydrocephalus is caused by the build-up of CSF in the brain ventricles
leading to increase in pressure on the brain tissue. CSF is produced in the choroid
plexus and flows through the brain chambers and the sub-arachnoid space. If this
flow is blocked or the absorption of excess CSF is hindered, hydrocephalus occurs
(Rekate, 2008). Communicating (non-obstructive) hydrocephalus refers to the
accumulation of CSF despite the absence of blockage; this could be explained by the
impairment of CSF reabsorption by the arachnoid granulations. On the other hand,
non-communicating hydrocephalus refers to the obstructive type which results from
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blockage in CSF flow. Moreover, hydrocephalus is classified into acquired,
occurring at any age due to injuries, stroke, tumors, meningitis or hemorrhages, and
congenital which is present at birth, mainly due to genetic factors (Tully & Dobyns,
2014). Furthermore, progressive hydrocephalus refers to increased intracranial
pressure that might need surgical intervention or non-progressive if the
hydrocephalus is not accompanied with any neurosurgical treatments (Kirkpatrick,
Engleman, & Minns, 1989). The reported child of family 1 in this study has
congenital communicating hydrocephalus with no associated abnormalities and near
normal development. The hydrocephalus was non-progressive and did not require
shunting. The affected child was found to have compound heterozygous variants in
the MPDZ gene. A single homozygous CH-causing mutation in this gene has been
recently reported in two individuals from two unrelated Saudi Arabian families. The
phenotype in these previously reported families is much more severe compared to the
patient described in here. In addition to a severe progressive hydrocephalus requiring
shunting, other abnormalities were reported in the affected individuals including
simplified gyration pattern in all of them, and coloboma with congenital heart disease
in one of them. In addition, there were two still births presumably due to CH in one
family and six CH cases in the second extended family. The cognitive outcome of the
two long term survivors in Al-Dosari et al. (2013) correlated with the speed of
neurosurgical intervention initiation after birth (Al-Dosari et al., 2013). Moreover,
five hydrocephalic stillbirths from three unrelated families were identified. Three
probands were genetically tested to find null mutations in MPDZ gene. Medical
termination was achieved to all fetuses except for one in whom the child died from
severe hydrocephalus (Saugier-Veber et al., 2017). Table 6 compares and lists all the
mutations in MPDZ gene reported so far in patients with congenital hydrocephalus.

Table 6: The reported MPDZ mutations in patients with congenital hydrocephalus
DNA Change

Protein Change

c.628C>T

p.(Gln210*)

No. of
Patients
1

Origin

c.628C>T

p.(Gln210*)

1

Saudi

c.1291_1294del

p.(Val431Metfs*14)

2 sibs

Senegalese

c.533+1G>T

Frame-shift

2

-

c.2248C>T

p.(Arg750*)

3 sibs

-

(Compound
heterozygous)
c.394G>A,

Predicted: p.Gly132Ser 1
Experimentally shown
to cause exon 5
skipping

c.1744C>G

p.Leu582Val

Saudi

Emirati

Phenotypes
Severe congenital
supratentorial hydrocephalus, mild
hypotonia, coloboma, atrial septal
defect
Severe congenital
supratentorial hydrocephalus
Massive hydrocephalus
Foetal macrosomia with
severe isolated ventriculomegaly
Recurrent hydrocephalus
Congenital non-progressive
communicating hydrocephalus with
normal developmental milestones

Ref.
(Al-Dosari et
al., 2013)

(Al-Dosari et
al., 2013)
(Saugier-Veber
et al., 2017)
(Saugier-Veber
et al., 2017)
(Saugier-Veber
et al., 2017)
Current study
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The null mutation reported by Al-Dosari et al. (2013), led to a truncation of
12 domains out of 13, abolishing most of the interactions with other proteins and
effectively leading to null effects and complete loss-of-function of the MPDZ
protein, which possibly had rendered the affected members severely hydrocephalic.
However, in our study, we detected a splice site and missense variants that might
provisionally affect domains (L27 and PDZ-1, as well as PDZ4, respectively).
MPDZ protein has many possibilities of interactions due to its multipledomain structure. Each domain is highly conserved among species and each is made
up of six beta sheets and two alpha helices (Figures 14B, C). Furthermore, the 13
PDZ domains are >50% homologous in rat MUPP1/MPDZ protein (Ullmer,
Schmuck, Figge, & Lübbert, 1998). I present in Figure 38 the alignment of the 13
domains in human MPDZ, showing homology in the preserved GLG loop, as well as
other locations. This loop lies between βA and βB sheets. It functions as a
coordinator for hydrogen bond of the C-terminal carboxylate group of the binder
protein. Another important domain in MPDZ is the hydrophobic pocket, which lies
between βB and αB, constituting the canonical binding sites for MPDZ. Opposite to
this binding groove, at about 30 residues C-terminal extension of the PDZ domain lie
other non-canonical binding sites (Gasteiger et al., 2003).

Figure 38: The alignment of the 13 PDZ domains in MPDZ protein of human, indicating the homologous regions in colored boxes showing a
graphical view of those conserved regions by Jalview (Clamp, Cuff, Searle, & Barton, 2004)
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The change from leucine (non-polar and bulkier side chain) to valine (nonpolar with smaller side chain) at position 582 is predicted to be disturbing the GLG
loop (Figure 14C). Despite the fact that glycine is neither at the GLG loop nor within
the hydrophobic pocket, it is predicted that the reported variant c.394G>A is in an
acceptor splice site region, leading to the generation of a stop codon, hence
truncating the majority of the protein domains, leaving the protein with only L27
domain.
The variant (c.394G>A) lies between L27 and PDZ1, PDZ-1 domain is
known to enhance binding of other PDZ domains. For example, PDZ-2 domain of
Syntenin (a PDZ domain that functions as an adaptor) binds neurexin, ephrin-1 and
syndecan only when paired with PDZ-1 (Hui, Xing, & Bader, 2013) (Grootjans,
Reekmans, Ceulemans, & David, 2000). Moreover, Grootjans et al. (2000) showed
that PATJ, a protein involved in cell polarity and a mammalian paralogue of MPDZ,
has a PDZ-1 domain linked to L27 domain. When they decreased both domains in
mammalian cell culture, it resulted in disassembly in tight junctions. Strikingly, they
had to be linked together for PATJ to function properly (Grootjans et al., 2000).
On the other hand, this variant has been predicted to cause a splice-site
aberration. Indeed, the absence of the mutated copy of mRNA that was revealed by
sequencing the cDNA for the mother and child suggested an NMD mechanism which
is consistent with the prediction of the Neural Network prediction tool. Following
that, we had to investigate the effect of that variant on MPDZ expression by
quantifying mRNA using real time PCR. Unfortunately, MPDZ is expressed at very
low levels in the hematopoietic lineages (https://www.ncbi.nlm.nih.gov/unigene).
However, transcripts could be detected in patient blood samples by RT-PCR,
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enabling further characterization of the mutant. However, tissue sources expressing
high amounts of MPDZ such as skin fibroblasts could not be obtained from the
patient. Consequently,

mutant and wild mini-gene constructs were designed to

analyze splicing variants (Desviat, Perez, & Ugarte, 2012), in order to verify the
effect of the variant (c.394G>A) on mRNA splicing and to reveal the possible
disease mechanism. Upon sequencing cDNAs from the resulting constructs, they
revealed the actual adjoining of the exons in the wild-type, while skipping of exon 5
of MPDZ gene within the mutant. This is explained by the fact that the variant
(c.394G>A) is located at the first nucleotide of exon 5 which was predicted to cause
a splice-site aberration (Figure 13).
With reference to the second variant of the compound heterozygous
mutations, the amino acid leucine, which is substituted at position (c.1744C>G), is
also conserved at that position among multiple species (Figure 13A). It lies between
βC sheet and αA of PDZ-4 domain. This change could be disease causing/probably
damaging according to Mutation Taster and PolyPhen (score 1.0), respectively. It has
been shown that binding of PDZ-5 domain of GRIP (Glutamate receptor interacting
protein) to its receptor GluR2 failed to occur in the absence of PDZ-4 domain,
indicating its role in the proper folding of the other domain (Hung & Sheng, 2002).
Although the change in our variant did not take place in any of the canonical binding
sites of MPDZ, function of PDZ-4 was not only restricted to such binding, rather
PDZ-4 was shown to be involved in the direct binding of PDZK1 (a MPDZ domaincontaining protein in hepatocytes which controls the expression and localization of
HDL receptors) to the inner leaflet of the cell membrane. This binding was not due to
any of the four PDZ domains in that protein, but to PDZ-4 solely (Tsukamoto et al.,
2013).
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It was assumed in this study that since MPDZ localizes at cell-cell adhesion
sites and is involved in regulating permeability, mutations in this protein would
disrupt this localization. Hence, alteration in CSF secretion would result in
hydrocephalus. After performing confocal microscopy on the wild type and mutant
plasmids, we observed no difference in the subcellular localization of either mutant
compared to the wild type. That was confirmed in HeLa as well as SH-SY5Y cells,
the latter cell line was used because it is a human cell line derived from a patient with
neuroblastoma and is used as a model for neuronal function and differentiation (La
Quaglia & Manchester, 1996). Therefore, we assume that the pathogenesis of these
missense changes is not due to trafficking defects; rather it could be due to disruption
or complete loss of the protein function or an essential protein-protein interaction. In
addition, all the reported variants in MPDZ gene listed in Table 6 have resulted in
more severe types due to the formation of null mutations, whereas the variants
identified in the current study might have retained partial function leading to less
severe phenotypes.
In conclusion, the identified compound heterozygous variants detected by
whole-exome sequencing and confirmed by Sanger sequencing in the affected child
are the most likely cause of his CH. The deleterious effects of the two variants have
been illustrated either experimentally or by bioinformatics tools. The clinical
presentation is consistent with CH which we strongly argue to be caused by the
compound heterozygous variants in MPDZ gene.
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4.2 Endoplasmic Reticulum Retention of Xylosyltransferase 1 (XYLT1) Mutants
Underlying Desbuquois Dysplasia type II
DBQD is a rare disease which is part of a group of disorders which are
characterized by multiple joint dislocations and therefore given the term ‘The
multiple dislocation group of disorders’. The main features of these bone dysplasias
include flat face with prominent eyes, joint laxity with dislocations of large joints,
and growth retardation (Alanay & Lachman, 2011). Radiologically, it is
characterized by short long bones with a monkey wrench appearance of the proximal
femora and advanced carpal and tarsal ossification. The presence of additional hand
anomalies (extra ossification center distal to the second metacarpal, delta phalanx,
and bifid distal phalanx of the thumb) in some patients has led to its classification
into DBQD type I (with additional hand anomalies) and DBQD type II (without such
anomalies) (Faivre et al., 2004) (Kaissi, Radler, Klaushofer, & Grill, 2009). The
patient in this report was classified as DBQD type II, as he had most of the clinical
and radiological features of DBQD including the mild monkey wrench abnormality
of the femora, but the typical hand anomalies seen in type I were absent. WES
analysis on this child revealed a novel variant in XYLT1 gene (c.2169dupA) resulting
in truncation (p.Val724Serfs*10) of the xylosyltransferase enzyme. This variant,
segregated with the phenotype among the family members and is expected to result
in a truncated protein, and immunofluorescent experiments demonstrated mislocalization resulting in a loss of XYLT1 function which is the first limiting step
among a series of enzymes (β1,4 galactosyltransferase1, β1,3 galactosyltransferase2,
and β1,3 glucosyltransferase 1) that are spatially related in glycosylation at the Golgi
apparatus (Figure 39) (Schreml et al., 2014).

Figure 39: Biosynthesis of Proteoglycans (PGs) and the enzymes involved in the GAG (Glycosaminoglycan) chains assembly.
XYLT1 initiates the addition of xylose followed by galactosyltransferases adding galactose, then glucosyltransferase adding
glucoronic acids.
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During bone development, chondrocytes are surrounded by PG rich matrix
that assists in their maturation, as well as the initiation of endochondral bone
formation. Defects in chondrocytes formation can lead to skeletal phenotypes (Eames
et al., 2011). PGs synthesis is initiated by XYLT1 enzymes through adding GAG
chains covalently, giving PGs the physiochemical features to withstand compression
forces (Schreml et al., 2014). Polymorphisms in XYLT1 gene were found to correlate
with decreased GAG levels (Ambrosius, Kleesiek, & Götting, 2009).
XYLT1 enzymes are expressed in chondrocytes during fetal development,
and in children during mineralization of osteoblasts (Prante, Kuhn, Kleesiek, &
Götting, 2009), aside from that, they localize at cis-Golgi where they exert their
catalytic function (Mis et al., 2014). Furthermore, reduction in the activity of XYLT1
was associated with a decremental growth of vertebral bones in animal models
(Morriss Jr, Fitzgerald, & Riddle, 1985). On the other hand, mutations in the other
enzymes involved in this pathway lead to other developmental disorders. For
example, mutations in B4GALT7 gene were found in patients affected by EhlersDanlos syndrome (Faiyaz-Ul-Haque et al., 2004), as well as patients affected by
short stature, hypermobility and hypotonia (Salter et al., 2016). Mutations in
B3GALT6 gene were as well recovered in Ehlers-Danlos syndrome patients (Malfait
et al., 2013) and Al-Gazali syndrome (Al Gazali, Al Talabani, Mosawi, & Lytle,
1994; Sellars, Bosanko, Lepard, Garnica, & Schaefer, 2014). Moreover, damaging
mutations in B3GAT3 gene were detected in patients with Peters Plus syndrome
(Lesnik Oberstein et al., 2006). All these syndromes included skeletal dysmorphisms
and dysmorphic features.
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The current functional study confirmed the mis-localization of the mutant
enzyme and its retention into the ER (Figures 21-23). This result was also noticed for
a previously reported missense mutation p.(Arg481Trp) introduced in this study and
which coincides with the finding of Schreml and colleagues done on patients’
fibroblasts showing loss of predominance of mutated XYLT1 in Golgi. Likewise, the
second generated missense mutation p.(Arg598Cys) which is located in the
xylosyltransferase domain and which was expected to be damaging being replaced
by a neutral amino acid (Bui et al., 2014), revealed the apparent retention of the
enzyme in the ER. It has been shown that retention in the ER is involved in the
cellular mechanism of several musculoskeletal abnormalities including Robinow
syndrome (Ali et al., 2007), and acromesomelic dysplasia-type Maroteaux (Hume et
al., 2009). To further confirm the retention of the mutant XYLT1 in the ER as was
shown by confocal studies and quantitative co-localization tests, we analyzed the
susceptibility of our glycoprotein to Endo H and PNGase F enzymes. Both of the
mutant and the wild types showed resistance to both enzymes (Figures 24A & B).
Glycoproteins are resistant to Endo H if they have complex oligosaccharides or
antennae-like structures (core structure) lacking the three linear mannoses
(Man1α3Man1α6Man1β (Trimble & Tarentino, 1991). In our case, the mutant
XYLT1 proteins were shown to be retained into the ER, and complex glycosylation
does not take place before the medial to trans-Golgi network (TGN) (Freeze &
Kranz, 2010). However, the wild type XYLT1 proteins were resistant to endo H
because they resided in the Golgi and must have got glycosylated to higher complex
forms. We hence thought that this assay might not be suitable to confirm the effect of
the mutation on the mis-localization, so we decided to further confirm that by
performing glycosidase test by PNGase F enzyme. PNGase F is known to cut the
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innermost (GlcNAc), leaving only asparagine attached to the core protein, it can cut
high mannose, hybrid, complex and multi-sialylated glycoproteins, even, tetraantennary and sulfate containing residues (Roth, Yehezkel, & Khalaila, 2012).
However, glycoproteins with α 1,3 fucose residue attached to the innermost fucose
bond are known to be resistant to PNGase F, they are found in plants and insects
(Wilson, Harthill, Mullin, Ashford, & Altmann, 1998), similarly, it has been also
detected in a few human glycoproteins such as transferrin (Fabini, Freilinger,
Altmann, & Wilson, 2001). Additionally, two α 1,3 fucosyltransferase genes (FUT10
and FUT11), although not verified experimentally, have been detected in human
genome by comparison (Becker & Lowe, 2003). Nevertheless, fucosylation at
position α 1,3 probably was not the reason for this resistance, since all the mutant
forms were proved to be localized in the ER, rather we attributed that to the location
of the N-glycosylation sites on XYLT1 proteins, and probably if the reaction was left
under extended incubation times (three days or more) could have shown effect on the
proteins, because PNGase F is a large enzyme (37 kDa) and its size can sometimes
hinder its accessibility to certain proteins. However, such conditions would possibly
affect the activity of the enzyme or the stability of the proteins. Moreover, another
explanation for the resistance is that XYLT1 protein has only three glycosylation
sites (slightly glycosylated), and left with only two in the truncated one
(p.val724fs*10), and it has been shown that the average size of the carbohydrate
chain in glycoproteins ranges between 1.5-3 kDa (Freeze & Kranz, 2010), which in
our proteins ranges from 3-9 kDa, and this difference in sizes between the cut and the
uncut forms cannot be demonstrated by western blotting (Figure 24).
In conclusion, the glycosidase sensitivity/resistance assay was not the test of
choice to further support the result obtained from the confocal study.
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XYLT1 enzyme is composed of two domains, the glycosyltransferase domain
(amino acids: 328-581) and the xylosyltransferase domain (amino acids: 613-794).
Thus, the truncation here will clearly omit most of the xylosyltransferase activity of
the enzyme (Bui et al., 2014). Figure 40 represents the position of our proband
variant (c.2169dupA, p.(Val724Serfs*10)) as well as all the previously reported
mutations relative to both domains. Bioinformatic analysis performed on our proband
predicted the termination to occur at position 732 deleting around 227 amino acids at
the c-terminal end of the protein including an important motif (745DWD747) which
was shown to be essential for the activity of XYLT1 (Götting, Kuhn, Zahn,
Brinkmann, & Kleesiek, 2000), unlike the N-terminus of XYLT1 which was proved
not to be involved in the function of UDP or heparin sulfate binding. Moreover, 20%
of the N-terminal region of the enzyme is not necessary for it to function, i.e, from
amino acid 1 to 260 of XYLT1, as truncation studies revealed. A 70% reduction of
the enzymatic activity was noticed when amino acids between 260 and 266 were
deleted, whereas, 91% loss resulted when Cys at position 276 was mutated. Although
the exact binding site to heparin is not yet determined, the presence of basic clusters
of amino acids throughout the whole enzyme is essential for its binding to its
substrates, and these clusters could be noticed at P721KKVFKI727, which has been
speculated to be responsible for the loss of activity due to induction of
conformational changes rather than reduced or inhibited binding to heparin (Müller
et al., 2006). Moreover, XYLT1 has three N-glycosylation sites; N-226, N-421, N777. Loss of the last glycosylation site due to truncation might affect the protein’s
stability and folding.

Figure 40: Schematic presentation of the 12 exons of XYLT1 protein indicating the positions of all the previously reported mutations in DBQD II
patients on the protein domains represented by patterned bars. (Red refers to the nonsense and frameshift mutations and black refers to the
missense mutations), (The asterisk points at our proband variant) domains represented by patterned bars.
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Schreml and colleagues studied XYLT1 expression in patient’s fibroblasts of
the variant (c.1441C>T, p.(Arg481Trp)) and found that there was no apparent
reduction in the enzyme expression. However, it led to defects in PG synthesis. On
the other hand, the variant (c.1290-2A>C) which affected a donor splice-site in two
unrelated Turkish families exhibited reduction in XYLT1 expression as well as a
decrease in chondroitin-sulfate PG (CS-PG). Similarly, the Mauritian family with
one affected individual with the variant (c.439C>T, p.(Arg147*), revealed a
reduction in CS-PG as well as XYLT1/2 expression, the latter being a paralog to
XYLT1 with high degree of homology (Bui et al., 2014). Currently, few patients
have been identified with homozygous mutations in XYLT1 gene segregating with
DBQD type II among different ethnicities, with nonsense, missense and splice-site
mutations (Table 7). However, the underlying cellular mechanisms of disease of
most of these mutations have not been fully elucidated.
In summary, we have identified a novel disease-causing XYLT1 variant
(c.2169dupA, p.(Val724Serfs*10)) and presented data to suggest that retention of
variant XYLT1 protein is the mechanism for decreased XYLT1 activity of several
mutations in this gene. Hence, we propose that a decrease in mature GAGs might be
the underlying disease mechanism for the disease, and this finding might be
considered a functional test in DBQD II patients associated with missense mutations
of unknown significance, to confirm pathogenicity.

Table 7: The genetic background of all the reported DBQD II affected patients
DNA change

Protein change

No. of
patients

Age
(years)

Origin

Consanguinity

Ref.

c.1792C>T
c.439C>T
c.276dup
c.1588-3C>T
c.1290-2A>C
c.1290-2A>C
c.1441C>T
c.1651C>T

p.Arg598Cys
p.Arg147*
p.Pro93Alafs*69
Exon skipping
Exon skipping
Exon skipping
p.Arg481Trp
p.(Arg551Cys)

2 sibs
1
1
1
1
1
2 sibs
1

24, 20
14
23
5.5
13
1
16, 18
11

Tunisian
Mauritian
Belgian
Turkish
Turkish
Turkish
Turkish
Brazilian

Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes

(Bui et al., 2014)
(Bui et al., 2014)
(Bui et al., 2014)
(Bui et al., 2014)
(Bui et al., 2014)
(Bui et al., 2014)
(Schreml et al., 2014)
(Silveira, Leal, &
Cavalcanti, 2016)

Compound
heterozygous
(c.595C>T, c.1651
C>T)
Compound
heterozygous
(c.1588-10_1595del,
3.3 Mb del)
c.2169dupA

p.(Gln199*),
p.(Arg551Cys)

1

7

Polish

No

(Jamsheer et al., 2016)

0-alleles

1 sib, 3
stillbirths

5 weeks

Dutch

No

(van Koningsbruggen et
al., 2016)

p.Val724Serfs*10

1

9

Emirati

Yes

Current study
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4.3 Possible Involvement of Variants in TSHZ3, LRRK2 and CRTAC1 Genes in
Monogenic Intellectual Disability
Intellectual disability (ID) is the most widely common neurodevelopmental
disorder characterized by intellectual and adaptive behaviors. It can be syndromic,
associated with other medical problems, or non-syndromic presented without any
other abnormality. The etiology of ID remains unknown in 30-50% of cases, yet, in
other cases they could be caused by genetic and/or environmental factors (Daily,
Ardinger, & Holmes, 2000). Because of the heterogeneous nature of ID, the number
of genes involved has been continuously increasing due to the great advances in
genotyping, DNA sequencing and bioinformatics technologies. Depending on the
genes involved and the nature of the mutation, phenotypes in ID syndromes vary
from mild to profound. In addition, it is not uncommon to find different mutations in
the same gene responsible for the syndromic or the non-syndromic types (Chiurazzi
& Pirozzi, 2016). Until November 2013, a list of 925 genes has been confirmed to
cause developmental disorders (Wright et al., 2015), with many more discovered
thenceforth
A neurodevelopmental disorder that has been genetically analyzed in the
current study is microcephaly. Microcephaly is a recessive autosomal disorder which
is characterized by small brain size (mainly the cortex) with normal architecture
(Woods, Bond, & Enard, 2005), the occipitofrontal circumference (OFC) is reduced
by at least 4 standard deviations. Autosomal recessive primary microcephaly
(MCPH) is generally, with exceptions, presented with normal height and weight as
well as normal chromosomal analysis (Mochida & Walsh, 2001). MCPH is
diagnosed prenatally and is non-progressive. On the other hand, secondary
microcephaly develops after birth and is a progressive condition. There are some
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factors that distinguish the primary type from the secondary, for example, primary
microcephaly most often occurs in consanguineous families, and in families with
history of multiple pregnancy losses, as well as early onset of microcephaly, and
normal early developmental milestones, all characterize the primary type (Qazi &
Reed, 1973). The incidence of MCPH ranges from 1.3-150/100,000 births depending
on levels of consanguinity (Kaindl et al., 2010). Neuronal progenitor cells divide into
symmetrical (cells dividing parallel to the neuroepithelium) or asymmetrical
orientations (cells dividing perpendicular to the neuroepithelium), the timing of such
divisions is critical during development (Finlay & Darlington, 1995). In addition,
disruption of the plane cell cleavage leads to microcephaly (Haldipur, Sivaprakasam,
Periasamy, Govindan, & Mani, 2015). Until January 2015, twelve loci have been
mapped in microcephalic patients harboring the following genes; ASPM, CENPJ,
STIL, CEP135, CEP152, ZNF335, PHC1, Microcephalin, WDR62, CDK5RAP2,
CASC5, and CDK6. The mechanisms of most of the genes are; disturbed mitosis,
abnormal chromosomal condensation, loss of DNA repair and microtubule dynamics
(Faheem et al., 2015).
The more severe ID forms typically occur early in life, and are usually
accompanied with dysmorphic features; these include malformations, deformations
and dysplasias. The effect of single gene mutations is often represented by
syndromes

such

as

dysmorphisms

(Reardon

&

Donnai,

2007).

If

the

dysmorphological pattern could not be matched to any of the known syndromes it
can lead to a serious diagnostic challenge, or it can be inaccurately referred to as a
novel syndrome. The discovery of novel genes implicated in several disorders has
accelerated recently, similarly, in the setting of dysmorphology. In 2016, a
geneticists group described 15 novel genes in 31 consanguineous families with
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individuals suffering from dysmorphic features, facilitating gene discovery among
geneticists (Shaheen et al., 2016).
The family here shows obvious features of autosomal recessive inheritance as
the pedigree shows in Figure 26. Homozygosity mapping implicated homozygous
regions on chromosomes 7, 9, 12, 14 and 19 with one of them presumed to be
harboring the causative gene. In addition, bioinformatics tools supported their
involvement in the disease. Furthermore, it was shown that one of the most important
factors determining the implication of a gene in a phenotype is its transcriptional
profile by using different databases which collected the mRNA data from expression
experiments (Chiurazzi & Pirozzi, 2016), such databases are listed in Table 1. The
expression profiles of the candidate genes of this family in Table 4 were retrieved
from gene cards database (www.genecards.org), it is obvious that most of the
candidate genes are abundantly expressed in most tissues, being overexpressed in
certain tissues more than others. However, EST (Expressed Sequence Tags) profiles
available at (https://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi) showed
that all the genes are expressed in brain at different levels, except for ENTPD8 gene,
which is mainly expressed in gastrointestinal tissues. Although we should expect that
most genes impairing cognition and affecting brain’s architecture should be
reasonably expressed in brain, it has been shown that the majority of syndromic ID
genes were expressed highly in other tissues as well (Chiurazzi & Pirozzi, 2016).
Several genes lay within long homozygous stretches of widths more than 22
Mbs, with TSHZ3 gene being there and therefore it was considered a strong
candidate. Although the identified variant in this gene (c.755A>G, p.Lys252Arg)
does not seem to be very severe due to the basic nature of both the ancestral and the

145
alternative amino acids. It is, however, possible that it could affect binding of TSHZ3
protein to the silencing complex; especially that the variant lies near the N-terminal
zinc fingers known to be responsible for the HDACs 1 and 2 binding (Kajiwara et al.,
2009). Moreover, the identified variant (Arg) lies within the sequence
(PRRWSKPRKR) which was predicted to be a nuclear localization signal (NLS) by
cNLS Mapper (Kosugi, Hasebe, Tomita, & Yanagawa, 2009). The functional assays
were designed to prove the effect of this variant on the protein’s ability to bind
HDACs 1 and 2 using western blotting. HEK293T cells were transfected with
TSHZ3 ORF expression vector (OriGene, USA) after mutating the desired
nucleotide, immunoprecipitated with anti-myc antibodies slurry, then HDAC 1 and 2
probed separately. Real-time PCR to quantify CASP4 was then performed. TSHZ3 is
known to form a silencing complex with other partners (SET, FE65 and HDACs) to
silence CASP4 expression (Kajiwara et al., 2009). However, the outcome of these
experiments were not convincing on implicating TSHZ3 as the cause for the observed
phenotype. We found that both the wild type and the mutant TSHZ3 proteins bound
HDACs 1 and 2 similarly (Figure 32), and the level of CASP4 expression was not
significantly changed in the patients mRNA compared to multiple normal controls
(Figure 33). We also examined the availability of other human or animal models with
mutations in TSHZ3 gene and in which the same phenotypes. We looked at
publically and some privately available data and identified another patient suffering
from microcephaly, moderate ID, global developmental delay and other phenotypes
with a compound heterozygous variants (c.3122A>C, p.Tyr1041Ser and c.1333G>A,
p.Val445Met) in TSHZ3. The allelic frequencies of these variants were 0.00008 and
0.0019836, respectively. In addition, two more patients had compound heterozygous
variants and homozygous variants who suffered from delayed speech, ID and other
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dysmorphic features, however, one of them had normal OFCs, while the other had +2
SD circumference (macrocephaly). Unfortunately, we were unable to carry out
detailed analysis of these patients at this stage. Attempts to identify individuals with
variants in this gene will continue.
TSHZ3 protein is highly expressed in the cerebral cortex, localizing in the
nuclei (www.proteinatlas.org). TSHZ3 proteins have been found to localize in the
cell bodies and the growth cones of the primary neuronal cultures in rats cortex
(Kajiwara et al., 2009). Likewise, STIL gene (reported in microcephalic patients) was
found to be expressed in the perinuclear region, assuming a role in the mitotic entry
(Kaindl et al., 2010). TSHZ3 encodes a transcription factor that regulates smooth
muscles differentiation. Mutant TSHZ3 in mice caused hydronephrosis and they
were unable to actively propel urine down to the bladder (Caubit et al., 2008). Not
only did mice develop kidney problems, but they also displayed learning difficulties.
TSHZ3 also regulates the development of neurons in respiratory rhythm and
airflow. Mice deficient for this protein failed to breathe and died soon after birth
(Caubit et al., 2010). However, these modules (knockouts) fully inactivate TSHZ3,
which might not be the case of the missense variant which we have identified,
probably these missense variants alter some of the TSHZ3 functions which we have
not yet identified.
Candidate-gene

criteria

scoring

system

had

shown

that

reported

microdeletions or duplications that harbor the gene of interest is considered a
weighted evidence for its candidacy (Farwell Hagman et al., 2017). In line with that,
Caubit X and his colleagues identified TSHZ3 to be the smallest region of overlapped
deletions after many studies have identified microdeletions in chromosome 19,
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spanning a number of genes in patients suffering from ID, developmental delays,
microcephaly, autistic features and other anomalies (Malan et al., 2009), (Kulharya,
Michaelis, Norris, Taylor, & Garcia-Heras, 1998), (Gana et al., 2012), (Castillo et al.,
2014), (Chowdhury et al., 2014). All deletions were heterozygous, suggesting
possible haploinsufficiency of TSHZ3 to cause the neurocognitive impairments
(Caubit et al., 2016).
Morpholino knockdowns, on the other hand, showed a dose-dependent loss of
the viscerocranium and the neural-crest derived cartilages of the anterior
neurocranium (Melvin et al., 2013).
The identified variant in the current study had a very low allelic frequency
(0.00019) in ExAC database, with only one individual carrying the same variant but
in a heterozygous state. The same variant did not exist in the exome variant server
and there was a single probably damaging missense variant in TSHZ3 gene in a
homozygous state in an African American individual out of 6447. Moreover, the
variant was absent in the Allele frequency database of Arab disease mutations
(GalaxC). Additionally, the variant was not available in the GME variome
sequencing project (http://www.igm.ucsd.edu/gme/).
The second strong candidate gene in family 3 was LRRK2, as noticed from
Table 3 that this gene lay within the longest homozygous stretch (27.8 Mbps). It is
expressed in most cells, indicating its involvement in basic cellular functions
(Alegre-Abarrategui et al., 2009). The identified variant (c.4325_4327delCTT) leads
to a deletion of alanine amino acid at position 1442. LRRK2 stands for Leucine Rich
Repeat Kinase 2, it encodes a protein of 2527 amino acids with multiple essential
domains such as a kinase domain, a DFG-like motif, a RAS domain, a GTPase
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domain, a MLK-like domain, and a WD40 domain (www.uniprot.org). A reported
mutation (Arg1441Cys), which is very close to ours, impaired the autophagic balance
by accumulating multi-vesicular bodies and autophagic vacuoles in several unrelated
patients affected by Parkinson disease (Wszolek et al., 1995). This variant was
located in the Ras of complex (ROC) domain with GTPase function, hence, it
appeared to enhance the kinase activity rather than the localization of LRRK2 protein
(West et al., 2005). In a crystallographic study performed on the following variants;
(p.Arg1441Cys, p.Arg1441Gly, and p.Arg1441His) identified in Parkinson patients,
the variants were located at the interface of two monomers crucial for the (ROC)
domain stability. Intriguingly, another substitution (p.Ala1442Pro), occurring at the
exact locus of our identified variant was also detected and it was suggested to disrupt
the region in a similar mechanism as the variants at position 1441 did (Deng et al.,
2008).
The identified variant in our study occurring at position 1442 could at least
similarly affect the stability of the ROC domain. In addition, the variant was not
found in the exome variant server, 1000 genome project, ExAC, GalaxC, GME and it
was predicted to be disease causing by Mutation Taster and deleterious of a high
score (-10.546), cut off value (-2.5) by Provean software (www.provean.jcvi.org).
LRRK2 gene is located within the biggest homozygous stretch (27.8 Mbs), and it is
highly expressed in the cerebellum and cerebral cortex.
Our main conclusion from these results is that TSHZ3 and the remaining
segregating genes cannot be excluded as a potential cause of the phenotype in family
3, hence, further justification of our conclusion can be achieved by proposing
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convincing assays that will address the issue and can effectively draw a conclusion
about the association of the identified gene (s) in the studied families.
Family 4 has four children; two of them are affected with ID, dysmorphic
features and anorectal anomalies, and two unaffected children born to a
consanguineous family (Figure 35A). Large homozygous intervals were mapped to
chromosomes 4, 5, 7, 8, 10, 12, 13, 14, 15, 16 and 18. The distance of the
homozygous regions harboring the candidate genes ranged from 10-18.5 Mbs (Figure
35B). The candidate genes that resulted from WES analysis were KMT2C, PDE1C,
CRTAC1, GIMAP2, NRXN3, and DSC3. Segregation analysis for all the candidate
genes was performed on all the family members by Sanger sequencing. The results
of sequencing identified a non-synonymous variant (c.1798G>A, p.Glu600Lys) in
CRTAC1 gene and it was the only gene segregating in the family (Figure 36). Hence,
further analyses were ceased on the remaining non-segregating genes. WES and
Sanger sequencing confirmed the variant in CRTAC1 gene. The change was predicted
to be disease-causing/deleterious by Mutation Taster/SIFT softwares, as the nature of
the change, from acidic to basic amino acid affects. The same variant did not exist in
the exome variant server; however, only one probably damaging variant in the same
gene existed in 3 individuals in a homozygous state out of 6216 European
Americans. However, the same variant existed in one South Asian individual in a
homozygous

state

with

allelic

frequency

of

0.0001818

(www.exac.broadinstitute.org).
CRTAC1 gene encodes cartilage acidic protein 1 which is an extracellular
protein found in deep articular cartilage. It is a marker used to differentiate
chondrocytes from osteoblasts (Steck et al., 2001b) (Steck et al., 2001a), a novel
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human marker gene for cultured chondrocytes. The encoded protein is made up of
661 amino acids, with an N-terminal signal of 27 amino acids and a c-terminal EGFlike domain (Winter et al., 2003). Besides its expression in chondrocytes, a smaller
transcript was shown to be as well expressed in brain and lung (Steck et al., 2001b).
The identified variant (p.Glu600Lys) is located within the EGF-like domain between
amino acid 559-605. It derived its name from epidermal growth factor which was
first identified in, containing 30-40 amino acids in the extracellular domain of the
membrane bound proteins or in secreted proteins, it is an evolutionary conserved
sequence and it contributes significantly to the function of the protein.
CRTAC1 gene is located at chromosome 10, cytogenic band 22q. Splice
variants generate two forms of the protein, CRTAC1-A and CRTAC1-B, both are
expressed in brain, such that isoform A lacks intron 14, exon 15 and intron 15,
whereas isoform B lacks intron 14 (Steck et al., 2007). Interestingly, the identified
variant is located in exon 14 which is highly conserved in all splice variants.
Furthermore, CRTAC1 protein was found to be highly conserved in vertebrates, and
more specifically the EGF-like Ca-binding domain where our variant is located
(Figure 37) and this binding is crucial for protein interactions. Moreover, several
human diseases have been associated with EGF-like domain containing proteins,
such as Marfan syndrome (Downing et al., 1996).
CRTAC1 protein binds to NgR1, a receptor of myelin-derived axon growth
inhibitors. The latter is responsible for the inhibition of neural regeneration in adults.
CRTAC1 suppresses NgR1. It was suggested that this suppression is crucial for the
normal neural development (Sato et al., 2011).
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Moreover, CRTAC1 protein is experimentally determined to interact with
MAPRE2 (Microtubule-Associated Protein, RP/EB family) (www.string-db.org).
MAPRE2 has been associated with several patients suffering from circumferential
skin creases, ID, cleft palate, short stature, and dysmorphic features (MIM 616734)
(Isrie et al., 2015).
To prove the causation of this variant to the phenotypes in family 4, designed
experiments to study the effect should be conducted from the previously shown
acquired data. It would be valuable for example, to test the binding ability of the
mutant CRTAC1 to calcium ions compared to normal controls. On the other hand,
clinical validity of the gene can be assessed with weighted evidences, and that could
be achieved by finding more reported cases from unrelated families carrying variants
in the same gene. Such that if three reported pathogenic variants were recovered in
unrelated individuals, the gene could be categorized as ‘limited’. In addition, the
availability of animal models presented with comparable phenotypes could assist in
providing more evidence. In addition, in vitro studies to demonstrate functional
disruption compliant with the disease, and which can be rescued in a cellular assay
give stronger evidence than model system does (Farwell Hagman et al., 2017).
In conclusion, candidate genes are reported when significant evidence is
provided. If the alteration in genes did not provide enough evidence to support its
clinical implication, it is often categorized under ‘uncharacterized genes with an
insufficient level of evidence’. These types of genes require corroborating evidence
in order to confirm their association with the disease. Moreover, showing that the
gene product interacts with another protein that was implicated in the same disease
provides a high level of certainty.
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Despite the fact that a large proportion of human diseases are caused by
mutations in the non-coding regions, we focused here on sequencing the 1-2% of the
human genome in order to identify causal genes. By this approach we could avoid
complexities and higher costs of WGS. However, drop in the cost and ease of
interpreting WGS huge data could replace WES in future. The human genome harbor
around 165 homozygous truncating variants (Robinson, Krawitz, & Mundlos, 2011),
which means that variants that appear to be pathogenic, do not necessarily relate to
the studied phenotype. Hence, bioinformatics assists in prioritizing such variants
referring to multiple tools and databases. During WES filtration, variants that are
included with the candidate genes due to certain criteria but do not relate to the
phenotype are considered false positive. On the other hand, some genes are poorly
covered by WES, leading to false negative results. Additionally, some variants could
be missed due to their distant enhancer regions.
In many consultation clinics, many diseases such as ID cannot be diagnosed
whether they are caused by autosomal recessive, multifactorial, environmental or by
de novo mutations. In such genetically heterogeneous diseases, de novo mutations
should not be under-appreciated.
Researchers could never be entirely certain the candidate gene is truly the
causative gene unless the same gene is identified in other unrelated families with
comparable phenotypes. Besides, the proof of a candidate gene comes from
experimental evidence as well as clinical and statistical data. Nowadays, the proof
requirements needed for new genes discovery are high, in order to meet the high
standards in human genomics (S. Richards et al., 2015). Sample size is as important
as any other evidence, although in very rare disorders it can be somehow difficult,
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thus, collaboration between geneticists, clinicians and scientists would be of great
importance in this case. Moreover, referring to genomic repositories could
alternatively reinforce the approach and avoid misleading directions.
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Chapter 5: Conclusions
Genetic disorders are caused by mutations in the human DNA. These
mutations vary from single base substitutions to gross deletions in one or more
chromosomes. Some disorders occur due to mutations in one gene and they are
therefore, referred to as “monogenic” or single gene disorders. Autosomal recessive
disorders are single gene disorders where deleterious mutations are passed from both
parents to offspring and for the phenotype to appear, both alleles must be mutated.
When parents are carriers, then there is a 25% chance to have an affected child for
each pregnancy who inherited both affected alleles from their parents. In the vast
majority of cases, carriers of the defective alleles are unaware of their status, and if
both parents were carriers, they are at high risk (25%) of passing the disease to their
children. The probability of both parents being carriers is significantly increased in
consanguineous marriages, because they inherit some identical genetic material from
a common ancestor. It is worth noting that the rates of consanguinity in most Arab
countries including the UAE is very high reaching 40-50% of all marriages. In fact in
the UAE, consanguinity exceeds 50% of all marriages, with most of those marriages
being first cousin unions. This clearly contributes to the increased rate of birth
defects in the country as well as other Arab and Middle Eastern populations.
Therefore, the major aim of this study was to elucidate the molecular and cellular
basis of several families with single gene disorders.
Robust genomic tools have significantly accelerated the discovery of
defective genes underlying monogenic disorders. The approach I have employed in
this project to identify novel disease genes is combining whole exome sequencing
using next generation sequencing with homozygosity mapping by performing whole
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genome SNP genotyping. The combination of mapping the homozygous regions
inherited in the families, which are most likely harboring the mutated gene, as well
as exploiting whole exome sequencing to identify pathogenic variants in the protein
coding regions and their flanking intronic regions, is an approach which has been
proved in recent years to be effective, and which enabled us to identify some
candidate genes for the phenotypes described in the affected families. Furthermore,
attaining experimental evidence to support pathogenicity and establish the cellular
mechanisms of diseases are very important approaches for accurate diagnosis as well
as prevention and management of diseases.
In family one (Section 3.1), I identified two compound heterozygous variants
in MPDZ gene detected by whole-exome sequencing and confirmed by Sanger
sequencing in the affected child. Additional experimental data suggested that these
variants are the most likely cause of congenital hydrocephalus in the affected child.
The deleterious effect of the first variant (c.394G>A, p.Gly132Ser) has been inferred
by NMD mechanism of mRNA to affect a splice-site region of one allele as shown
by sequencing the cDNA from the patient, and by constructing a mini-gene plasmid
with the same variant; I was able to demonstrate exon skipping in MPDZ gene
comparing it to a plasmid harboring the wild-type part of the gene. In addition,
bioinformatics and protein modeling data provided evidence on the pathogenicity of
the missense variant (c.1744C>G, p.Leu582Val). In addition, the clinical
presentation was consistent with CH and we therefore concluded that the phenotype
in the affected child was most likely caused by the identified compound
heterozygous variants in the MPDZ gene. Our findings on this family are in line with
other reported in a small number of patients with CH having mutations in MPDZ
gene. Mutations in this gene have been reported in a small number of patients from
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Saudi Arabia and Senegal as presented in Table 6. Therefore, our findings further
confirm the involvement of this gene in CH and its functional importance in cell-cell
adhesion and permeability in humans, and the fact that the protein is expressed in
brain and neuronal tissues.
In family 2 (Section 3.2), we identified a novel disease-causing XYLT1
variant (c.2169dupA, p.(Val724Serfs*10)) and presented data to suggest that
retention of XYLT1 mutant proteins in the ER as the underlying mechanism for
decreased XYLT1 activity of several reported mutations in this gene. This was based
on

generating

these

mutants

(c.1441C>T,

p.Arg481Trp

and

c.1792C>T,

p.Arg598Cys and c.2169dupA, p.Val724Serfz*10) in XYLT1 cDNA cloned into a
mammalian expression vector. Hence, decrease in mature GAGs could possibly be
the underlying disease mechanism for DBQD II, and this approach might be
considered a functional test in newly diagnosed patients associated with missense
mutations of unknown significance, to confirm pathogenicity.
In families 3 and 4, affected children suffered from monogenic ID
syndromes. The approach we employed was combining two major technologies to
identify the candidate genes; homozygosity mapping by obtaining genome-wide SNP
array of all family members and next generation sequencing of all the exons and
splice sites of most known genes within the genomes of the affected individuals. In
family 3 (Section 3.3.1), two siblings suffering from ID, microcephaly and muscle
hypotonia were analyzed, and I was able to identify six candidate genes based on the
pipeline mentioned in section 1.4.4.5. However, it is not uncommon that new
candidate genes could not be easily and successfully verified experimentally. In this
case, validation of more unrelated patients could facilitate the gene’s implication in
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the disease. We therefore submitted our data to common databases to get connected
with scientists with patients exhibiting variants of unknown significance in the same
genes. Furthermore, combining expression analyses and protein interactions links the
prediction of candidate genes to the diseases. Moreover, designing future
experimental assays that could show true gene association with the given diseases
plays a significant role in gene discovery.
Some functional assays were performed on patients of family 3 in order to
correlate the candidate gene (TSHZ3) with the phenotypes. It was hypothesized that
the mutant TSHZ3 protein will not be able to cooperate with FE65, HDAC1 and
HDAC2, hence to the promoter region of CASP4 gene. This in turn, would lead to
increased expression of CASP4. Accordingly, patient’s cDNA was quantified by
real-time PCR, and compared with multiple healthy controls to prove whether the
identified variant could alter CASP4 expression. In addition, binding assay was
performed on the mutant TSHZ3 overexpressed protein versus the wild-type to
assess their interaction with the silencing complex using WB technique.
Unfortunately, our experiment data on this family are still not enough to claim a
definitive conclusion on the possible involvement of TSHZ3 gene in the disease. We
will therefore, seek additional evidences which could include recruitment of other
patients, animal models or other functional assays. Similarly, the identified candidate
gene (CRTAC1) in family 4, with two siblings suffering from ID, dysmorphic
features and anorectal anomalies, showed high preference amongst the other genes.
Interestingly, CRTAC1 was the only gene segregating with the phenotype among the
family members. Besides, bioinformatics analyses predicted the variant (c.1798G>A,
p.Glu600Lys) to be pathogenic; as it was located within the EGF-like domain of the
protein, and that the mutated amino acid is highly conserved among vertebrates.
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These initial studies demonstrated favorable argumentation to look deeply
into the relation between the identified variants and the studied diseases. The main
outcomes of such experiments should explain the severity of the variants on the
patients, supported by relevant animal model or the presence of multiple affected
unrelated individuals carrying pathogenic variants on the same genes.
5.1 Potential Implications and Limitations of the Study
Despite recent advances made in the genomic and bioinformatics tools,
discovering new genes underlying inherited disorders, such as monogenic disorders
has proven to be challenging in significant number of cases. Powerful approaches are
needed to link newly discovered genes to the current diseases. Next generation
sequencing, SNP genotyping and CGH array, in addition to computational and
bioinformatics tools have already been used in this study, followed by experimental
studies, to functionally validate their association with the diseases. While not all the
candidate genes have proved their implication in the studied patients, it is expected
that there will be many to fulfill, by implementing more experiments.
In this dissertation, I studied four families with presumed autosomal recessive
single-gene disorders and the findings can be briefly summarized as:


Established the association of two MPDZ gene novel variants in the
pathogenesis

of

a

mild

non-progressive

communicating

congenital

hydrocephalic patient.


Established the causative effect of a novel variant in XYLT1 gene in a patient
affected by DBQD II.
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Established the cellular mechanism and involvement of the ER quality
control in the pathogenesis of three disease-causing variants in XYLT1.



Identified THSZ3 and LRRK2 as possible candidate genes in a family with
monogeneic intellectual disability characterized by microcephaly, ID and
muscle hypotonia.



Identified CRTAC1 as the candidate gene in a family with monogenic
intellectual disability characterized by dysmorphic features, ID and anorectal
anomalies.

5.2 Future Perspectives
In order to evaluate the evidence of the gene variants identified in this study
whether they exert major effects on the patients or not, we should outline reasons to
corroborate their candidacy. This could be obtained by executing functional assays to
include or exclude those genes.
Two families (3 and 4) were analyzed by WES and homozygosity mapping
combined with bioinformatics to assess the discovery of the involved genes. In
family 3 where the affected children suffered from microcephaly, ID and muscle
hypotonia, two functional analyses were performed based on postulated hypotheses
mentioned in previous chapters. However, the performed experiments could not
prove the effect on the disease mechanism. Nevertheless, while this explains why we
were not able to prove the candidacy of TSHZ3 gene, it also shows that we were not
misled by a false-positive variant, given other presented supportive data. In this
context we aim at performing the following functional assays on the studied families:
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The highly ranked candidate gene in family 3 was TSHZ3 gene. As the
variant

(p.Lys252Arg)

lies

within

a

nuclear

localization

signal

(PRRWSKPRKR), we propose studying the localization of the wild/mutant
TSHZ3 protein in different cell lines.


The second strongest candidate gene identified in family 3 was LRRK2. The
variant (p.Ala1442del) was located in (Ras of Complex) (ROC) domain,
which acts as a GTPase to regulate protein kinase activity. Protein modeling
of the mutant LRKK2 can be designed to study its effect on the stability of
the ROC dimers.



As CRTAC1 gene has the only segregating variant with the phenotype in
family 4. The variant (p.Glu600Lys) is located within the EGF-like domain
which binds calcium ions crucial for protein interactions, thus, it would be
valuable for example, to test the binding ability of the mutant CRTAC1 to
calcium ions compared to normal controls.
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